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Hypothesis 
If staphylococcal biofilms are exposed to clinically relevant doses and combinations 
of antibiotics, a variable amount of biofilm eradication will be observed, as some 
regimes are more effective than others. 
Abstract 
Introduction 
Joint replacement is a common and effective procedure but unfortunately, a small 
proportion of patients develop Prosthetic joint Infection (PJI). The bacteria 
responsible for these infections exist within a surface -associated community known 
as a biofilm. When this biofilm phenotype is expressed, it allows the organisms to 
resist phagocytic host defenses, tolerate the stresses induced by antimicrobials and 
colonize peri- prosthetic niches. PJI is invariably refractory to standard therapies 
and clinicians are required to use a combination of systemic and local 
antimicrobials, repeated debridement and prosthesis exchange to treat the patient 
resulting in significant morbidity. Standard antibiotic sensitivity tests offer little 
insight into bacterial susceptibilities in the biofilm state. Furthermore, they neither 
test at the higher levels, nor in the combinations of antibiotics that are commonly 
locally delivered during surgery. The aim of this thesis was to develop and validate 
a biofilm model, and to use it to test staphylococcal biofilms with clinically 
achievable concentrations of antibiotics in combination. 
Methods 
Sodium alginate gel was chelated with a calcium chloride solution to form bullet 
shaped beads with a surface area of 161mm2 These beads were then removed and 
their surface inoculated with either a methicillin sensitive Staphylococcus aureus 
(ATCC 29213) or a clinical strain of coagulase negative staphylococcus. After being 
incubated aerobically for 20 hours in a 48 -well micro -titre plate, growth controls 
were sampled and enumerated. The remaining beads were washed to remove non - 
adherent bacteria and placed into fresh broth containing antibiotics. After 3 hours 
of antibiotic challenge, they were removed, washed and the biofilm detached by 
dissolving the bead in a citric acid and Na2CO3 solution. Viable organisms were 
enumerated after micro -dilution and Miles Misra plating onto agar. 
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Results 
Cryo -scanning electron microscopy demonstrated the model allowed a biofilm to 
develop on the surface of alginate beads. Overall the technique performed with 
satisfactory resemblance of the control data and acceptable responsiveness after 
disinfection. The repeatability of disinfection was found to be most variable around 
the level used to define bacterial eradication. The model was used to compare the 
minimum inhibitory (MIC) and biofilm eradication concentrations (MBEC) of seven 
commonly used antibiotics. Poor correlation was found between the susceptibility 
of the standard planktonic cultures to antibiotics and those that were effective 
against organisms in biofilm. Gentamicin and daptomycin were found to be the 
only mono -therapies that were effective against the biofilm at clinically achievable 
levels. Combining antibiotics that were ineffective as single agents did not confer 
additional benefit. 
Interestingly despite gentamicin being effective when tested alone, combining it 
with clindamycin, rifampacin or linezolid reduced the bactericidal effect markedly 
in both strains. This phenomenon was investigated further by varying the 
concentration of antibiotics within the combinations. Combining the bactericidal 
antibiotics tested with gentamicin had an additive or synergistic effect. More 
importantly, a strong antagonistic effect was observed, with between 8 and 32 times 
more gentamicin being required, when it was combined with antibiotics considered 
bacteriostatic. 
Conclusion 
Standard microbiology laboratory testing is inadequate to guide clinical treatment 
of PJI. Testing of biofilm susceptibility to combinations of antimicrobials at high 
concentrations should be included in the laboratory testing of PJI. Further research 
should be directed towards understanding the mechanisms in which bacteriostatic 
antibiotics induce the organisms to become more tolerant to other antibiotics. 
If the antagonistic effect is confirmed in -vivo then it is logical to study a two stage 
antimicrobial strategy, avoiding potential antagonism by only introducing 





compound possessing both hydrophilic and lipophilic properties e.g. 
detergent. 
ANOVA 
Analysis of variance is a statistical method for making simultaneous comparisons 
between two or more means 
ALAC spacer Antibiotic loaded acrylic cement is fashioned into an 
anatomic shape and used as a 
temporary prosthesis between surgical procedures. 
Anaerobe - 
facultative Bacteria that can grow without oxygen but can utilise oxygen if it is present 
Anaerobe - 
aerotolerant 
Bacteria which cannot use oxygen for growth, but can tolerate the presence of it 
Anaerobe - 
obligate 
Bacteria which is harmed by the presence of oxygen 
Arthroplasty A procedure where a natural joint is reconstructed with an artificial prosthesis. 
Arthroplasty - 
excision 
A procedure where the articular ends of the bones are simply excised, so that a gap 
is created between them, or when a joint replacement is removed and not replaced 
by another prosthesis. 
Arthroplasty - 
primary 
The first time a total joint replacement operation is performed on any individual 
joint in a patient. 
Auxotrophic Inability of an organism to synthesize a particular organic compound required for its growth 
Biofilm 
A heterogeneous aggregate of micro -organisms who are adherent to a surface, 
embedded within a self -produced extracellular matrix and exhibit an altered 
phenotype with respect to growth rate and gene transcription 
Body mass 
index 
A statistical tool used to estimate a healthy body weight based on an individual's 
height. The BMI is calculated by dividing a person's weight (kg) by the square of 
their height (m2). 
Bone cement 
The material used to fix cemented joint replacements to bone - polymethyl- 
methacrylate (PMMA). Antibiotic can be added to bone cement to try and reduce 
the risk of and treat established infection. 
Chaperone Protein that assists the folding or unfolding of other macromolecular structures 
CNS Coagulase negative staphylococcus 
Debridement Surgical removal of dead, damaged, or infected tissue to improve the healing potential of the remaining healthy tissue. 
ETC 
The electron transfer chain is a sequence of electron carrier molecules or membrane 
proteins that shuttle electrons during the redox reactions that release energy used to 
power the cell. 
HR Hazards Ratio are an expression of the chance of events occurring in the treatment arm as a ratio of the hazard of the events occurring in the control arm 
Homologues Having the same or allelic genes with genetic loci usually arranged in the same order 
Horizontal 
gene transfer 
Acquisition of genetic information by transfers from an organism that is not its 
parent, typically a member of a different species. 
[LR] 
Likelihood ratio is the chance that a given test result would be expected in a patient 
with the disorder compared to a patient without the disorder 
LMWH Low molecular weight heparin. 
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LD 
Log density is a measure of bacterial number. Calculated by log io converting the 
number of colony forming units enumerated. 
LR 
Log reduction is the difference between LD of growth controls and LD of biofilms 
exposed and antimicrobials. 
MSSA Methicillin sensitive Staphylococcus aureus 
MBC 
Minimum bactericidal concentration is lowest concentration of antibiotic that 
inhibits subsequent planktonic subculture. 
MBEC The minimum biofilm eradication concentration is concentration of antimicrobial that eradicates 99.9% of the bacterial biofilm. 
MIC Minimum inhibitory concentration is the lowest concentration 
of antibiotic that 
inhibits overnight growth in a planktonic culture 
NCP Normal colony phenotype 
OR 
The odds ratio represents the chance that an outcome will occur given a particular 
exposure, compared to the odds of the outcome occurring in absence of exposure. 
Operon A unit made up of linked genes that is thought to regulate other genes responsible for protein synthesis. 
PMF Proto- motive force 
Parenteral Introduction of substance into the body via a route other than the mouth, especially via intra- venous infusion 
Pharmaco- 
dynamics 
Study of relationship between antibiotic concentration and pharmacologic effect or 
microorganism death. 
Pharmaco- 
kinetics Study of relationship between antibiotic concentration and time or dosing regimes. 
Prosthetic An artificial body part usually internally implanted but can be removable. 
Prosthetic joint 
infection 
Bacterial or fungal infection surrounding an artificial joint replacement. 
Subcategory of prosthetic related infection that encompasses infection of any 
implanted material in the host. 
Putative Commonly regarded as such; reputed; supposed 
Quorum 
sensing 
Derived from legal term denoting minimum number of members required to make a 
decision. Bacteria have evolved sophisticated cell -cell communication systems that 
allow them to orchestrate the expression of different phenotypic states 
Revision Operation performed to remove (and usually replace) one or more components of a total joint prosthesis for whatever reason. 
Revision 
single stage 
A revision carried out in a single operation 
Revision 
two -stage 
A revision procedure carried out as two operations, often used in the treatment of 
deep infection. 
Sinus A channel connecting the skin with an underlying suppurative wound. 
SCV 
Small colony variant is a bacterial phenotype that displays auxotrophism, forms 
slow growing poorly pigmented, small colonies on agar plate and expresses an 
altered pattern of virulence and tolerance to antimicrobials 
Standard 
deviation 
Measure of the spread of the data about the average. The smaller the standard 
deviation, the less spread out the data. 
Stochastic A random probability pattern that may be analysed statistically but may not be predicted precisely. 
Tolerant Reduced efficacy of antibiotics in the absence of genotypic resistance. 
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1.1. Prosthetic related infection 
1.1.1. Historical view of prosthetics 
The ability to secure resources necessary for the replication of our genome is 
universal to all life on Earth today. What has distinguished Homo sapiens 
from the other tens of millions of species that exist', was our ability to 
develop technologies which allowed us to augment our hunting ability, 
migrate to every continent, farm other species and latterly test and rapidly 
communicate abstract concepts such as the ones contained within this thesis. 
Not content just to adapt our environment, humans have demonstrated a 
widespread desire to modify their own bodies for social, religious or 
functional reasons. The first recorded example of this is the 5,300 year -old 
Ötzi the Iceman, who was found in a glacier in Austria sporting some gold 
earrings'. There are also several reports of the Incas performing 
crainoplasties with gold plates to cover trephine defects 4,200 years ago3. 
These procedures did not advance significantly for the next 4000 years and 
surgery was limited to amputation or evacuation of pus until modern 
anaesthesia with chloroform or diethyl ether, was developed in the 1840's by 
James Simpson and William Morton respectively. Europe's first operation 
using ether was a leg amputation performed by Robert Liston on December 
21st 1846 at the University College Hospital London. A contemporaneous 
description of the procedure highlighted why the mortality rate from post- 
operative infection was 50 -60 %4: 
'Everyone swore that the first flash of his knife was followed so 
swiftly by the rasp of saw on bone that sight and sound seemed 
simultaneous. To free both hands, he would clasp the bloody knife between 
his teeth.' 
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It was not until Joseph Lister built on the work of Pasteur and described 
aseptic surgical techniques in his 1867 thesis', that implanting biomaterials 
became more popular. As the intra- operative and post- operative risks 
lessened surgeons started to use biomaterials to repair, re- orientate and 
replace parts of the musculoskeletal system aiming to alleviate pain and 
restore function to their patients. Hansmann first described reconstruction of 
fractured limbs with metal plates and screws in 1886. The first 
endoprosthesis was invented and implanted in 1890 by Themisocles Gluck, 
in the form of a hinged ivory knee replacement used to replace a tuberculous 
knee joint'. Although it allowed the patient to mobilise pain free after a 
month, it later had to be removed because of prosthetic infection. 
As hip replacement evolved from interpositional and hemi -arthroplasty 
between 1920 and 1950 it became evident that despite careful antisepsis, 
infection was prevalent after implantation of prosthetic material and research 
began to understand the mechanisms. Elek and Conen demonstrated in 26 
human volunteers', that the minimum inoculum of Staphylococcus aureus 
necessary to cause a superficial abscess in their skin reduced from 10 million 
to just 200 when they were introduced around a silk suture. A number of 
researchers have subsequently identified that the granulocytes that 
accumulate around biomaterials become "frustrated' by their futile attempts 
to attack the implant, develop a functional defect that impairs superoxide 
production and phagocytosis 8. 
Total hip replacement was popularised after Sir John Charnley made a 
number of important advances in the 1960's (Figure 1.1). He introduced 
bone cement as an interface between the prosthesis and bone, he also 
conceptualised low friction arthroplasty, reducing wear between the bearing 
surfaces. His initial deep infection rates were 9% but with a series of 
adaptations, including cleaner air flow reducing intra- operative aerosol 
contamination, his infection rate fell 10 fold by 19709. Joint replacement is 
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just one example in medicine today of how our desire to modify our own 
bodies has presented microorganisms with a new peri- prosthetic niche to 
colonise and exploit. Although the pathophysiology of prosthetic related 
infection is similar no matter where it occurs in the body, the focus of this 
thesis will be when it occurs after joint arthroplasty and causes a Prosthetic 
Joint Infection (PTI). 
Figure 1.1. A radiograph showing bilateral hip replacements. 
The right hand side of the page shows Charnley's design and the left is a stem designed in Exeter that 
is currently popular. The cement mantle that supports the metal stems and polyethylene cups appears 
more radio dense than the surrounding bone. 
1.1.2. Current use of prosthetic joints in the UK 
In 2011, over 160,000 primary total hip and knee replacement procedures 
were performed in the UK in approximately equal proportion'''. 
Worldwide sales figures showed 1.4 million hip and 1.1 million knee 
replacements were sold in 201112. It is one of the most rewarding operations 
a surgeon can perform, reducing pain and increasing physical function in the 
vast majority of patients. It also presents good value for money compared to 
other medical interventions with the mean cost per Quality- Adjusted Life 
Year (QALY)13 has been determined to be £5,728 for primary hip and £11,947 
for primary knee replacement14. A commonly used threshold level for the 
cost per QALY that is deemed to be good value is £25,000 -43,000. 
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Despite precautions, major complications such as component dislocation, 
death from medical complications and prosthetic infection are inevitable in a 
proportion of patients. Specialist arthroplasty units with high throughput 
generally report a deep infection rate of around 0.5 -1% but range up to 4% in 
some general hospitals11,15'16 Although revision surgery costs around 
£20,500, which is more than three times the cost of the primary procedure'', 
it is not the greatest associated burden. PJI also entails significant patient 
morbidity with weeks in hospital recovering from painful surgery and is an 
emotionally draining experience for the healthcare professionals involved. 
1.13. Definition of prosthetic joint infection 
The recent 'Infectious Diseases Society of America Guidelines'20 reviewed the 
current literature and defined definite prosthetic joint infection as: "the 
presence of a sinus tract that communicates with the prosthesis or purulence 
surrounding the prosthesis without another known etiology or two or more 
cultures that yield the same organism ". Findings that are also highly 
suggestive of PJI include the presence of acute inflammation seen on histo- 
pathologic examination of peri- prosthetic tissue, or the growth of a virulent 
microorganism (e.g. S. aureus) in a single specimen of a tissue biopsy or 
synovial fluid. The presence of PJI is possible even if the criteria are not met 
and the clinician should apply clinical judgment. 
1.1.4. Diagnosis of prosthetic joint infection 
Clinical features of PJI vary depending on the time from surgery and the 
responsible organism. Around 2 /3' of all PJI present within the first few 
weeks post- operatively16. Persistent wound drainage is typical with systemic 
upset and local inflammation if caused by a more virulent organism. If 
infection presents after this period but within the first year, then a less 
virulent organism is typically responsible and patients frequently report that 
their original pain was never abolished, or has returned. Clinically the limb 
can be oedematous with a woody character to the soft tissue envelope, 
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secondary to the inflammation. If the infection occurs after a year then it is 
more likely to represent haematogenous spread of a more virulent organism 
and present with systemic symptoms. 
Once PJI is suspected it must be investigated by a thorough history and 
physical examination. The history should include the onset of and current 
clinical symptoms, the exact date of implantation, the type of prosthesis and 
whether Antibiotic Loaded Acrylic Bone Cement was used (ALAC). 
Enquiries into previous surgical history, wound healing problems following 
joint implantation, concurrent infections, drug allergies and co- morbid 
conditions should be made. Relevant microbiology results from aspirations 
and intra- operative samples, as well as previous antimicrobial therapy and 
inflammatory indices should be detailed. 
1.1.5. Investigation of suspected PJI 
Two orthogonal plain radiographs of the joint should be obtained to assess 
mechanical loosening and remaining bone stock. Routine use of bone scans, 
leukocyte scans, magnetic resonance imaging, computed tomography, and 
positron emission tomography scans are not indicated. 
Laboratory blood tests including Erythrocyte Sedimentation Rate (ESR) and 
C- Reactive Protein (CRP) should be performed in all patients and blood 
cultures should be taken if there is systemic upset with fever. CRP is acute 
phase protein, produced by the liver and is a maker of systemic 
inflammation. Its plasma concentration rises dramatically after arthroplasty 
with peak concentration on day 2 but generally returns to normal ( <10 
mg /dl) in 3 -4 weeks following joint arthroplasty21. Berbari et al.22 included 30 
studies in their meta -analysis to determine the usefulness of inflammatory 
markers at predicting the presence of infection in patients suspected of 
having PJI. They found CRP had a sensitivity of 88% and specificity of 74% 
whilst ESR had a sensitivity of 75% and specificity of 70 %. Combining them 
showed an increase in their diagnostic Odds Ratios [OR] to 89 reflecting 
improved accuracy whist remaining independent to prevalence. Berbari's 
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meta -analysis found interleukin -6 to be the most sensitive and specific 
marker but as its use is limited to a few specialist centres and it is not 
currently recommended. 
A diagnostic joint aspiration should be performed in all patients with 
suspected PJI before antibiotics are given. Analysis of the synovial fluid 
should include a leukocyte count and extended 14 -day culture for aerobic 
and anaerobic organisms. Schafer et al.23 showed in a well -conducted study 
that 1/4 of organisms (typically Propionibacterium spp) were only identified 
in cultures between 7 to 14 days. Importantly they demonstrated the clinical 
significance of these organisms with the association between >_ 2 culture - 
positive tissue samples and positive histological analysis. The OSIRIS group' 
demonstrated by increasing the cutoff to two or more specimens growing the 
same organism raises the positive Likelihood Ratio [LR] to 25.9, which is 
highly predictive of infection (sensitivity, 71 %; specificity, 97 %; post -test 
probability of infection, 80.6 %). 
If antibiotics have been started and the patient is not clinically unwell, then 
withholding antimicrobial therapy for 2 weeks prior to aspiration increases 
the positive identification rate from 41% to 77 %. However, if patients had 
received antimicrobial therapy within 2 weeks of revision, then culture after 
sonication of the prostheses is a more sensitive method than conventional 
culture of peri- prosthetic tissue (75% and 45 %, p <0.001)25. Interestingly 
however, it has been demonstrated that a single dose of pre- operative 
antibiotic at induction of anesthetic does not alter the culture results of 
positive intra- operative specimens26. 
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1.1.6. Risk factors for developing prosthetic joint infection 
An understanding of patient, intra- operative and post- operative factors 
associated with PJI (Table 1.1) is needed if clinicians are to take steps to 
mitigate them. Some risk factors like the use of surgical drains are easy to 
avoid once they are known to be detrimental. Others such as previous joint 
surgery or being male cannot be modified and in these circumstances it is 
vital for the patient to be counseled and weigh up the advantages and 
disadvantages of the procedure before granting their consent. 
Using bone cement that is loaded with antibiotics is generally accepted to 
lower the risk of PJI. It is of note though, when Parvizi performed a meta - 
analysis of 15,000 hip replacements27 which showed that 6 / 8 of the studies 
demonstrated reduced infection with antibiotic cement, only the largest 
study (with around 75% of all hips studied)28 actually demonstrated an effect 
that was statistically significant. This helps explain why their Forest plot, 
using weighted means, demonstrated overall a statistically significant 
reduction in infection by around 50% (1.2% vs. 2.3 %). 
Engesaeter et al.29 analysed the outcome of 56,275 joint replacements collected 
in the Norwegian arthroplasty register and found that the risk of implant 
revision was lowest if ALAC was used in combination with 4 doses of 
systemic antibiotic on the day of surgery. Patients who only received 
systemic prophylaxis had a 1.3 times higher revision rate for aseptic 
loosening than the group in whom ALAC was used. This suggests a 
proportion of revisions carried out for 'aseptic' loosening are probably 
associated with low -grade infection. Registries do not however, provide 
information about true infection rates as their primary outcome is a revision 
or re- operation and can underestimate PJI incidence by a quarter's 
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Factors Major Risks Lesser Risks 
Patient 
Related 
Malignancy [OR 3]19 
Rheumatoid Arthritis 
BMI >40 [OR 6.4] 30,31 
Warfarin 
Bacteraemia 
Avascular necrosis [OR 3.7]32 
Post traumatic arthritis [or 3.2]32 
Male [OR 1.9- 2.213233 
Diabetes [OR 1.28 -2.3] 30,32 
Psoriasis or dermatitis 
Immunosuppression 
Malnourishment 




Excessive surgical time [OR2.8]32,33 
Revision Surgery [OR 2119 
Use of a wound drain [OR 134 
P [OR Preoperative LMWH 6.2 
NNIS score > 2 [OR 4]19 
Inadequate skin closure 
Not using prophylactic 
antibiotics [OR 4]36 
Not using ultraclean air 
filters [OR 2.6136 
Post- 
operative 
Early wound infection [OR 36]19 
Haematoma [OR 1437 
Uncontrolled INR [OR 2.4]34 
Wound leakage after 7 days 
Skin blisters 
Concurrent UTI 
Table 1.1: Risk factors for developing prosthetic related infection. 
[OR] -Odds ratios should the patient be exposed to that particular risk. LMWH -low 
molecular weight heparin, UTI - urinary tract infection, NNIS - National 
Nosocomial Infections Surveillance risk index38. BMI- Body mass index. UTI - 
urinary tract infection. INR - International Normalized Ratio of prothrombin time 
is a measure of coagulation. 
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Although there have been two recent studies that did not find ALAC 
lowered the 1 -year infection rate, there are important differences between 
them and previous studies. Namba et al.32 identified 56,216 primary knee 
replacements using registry data to identify that a higher proportion of 
patients with deep infection had received ALAC, (18.8% compared to 12.0% 
of patients without infection p >0.001). Although the multi- variant analysis 
will have controlled for some of the confounding factors, there were enough 
other apparently spurious associations to make residual confounding factors 
very likely. For instance they also found that low volume centers had 0.33 
Hazards Ratios [HR] (see glossary) compared to high volume centers and 
that clean laminar air did not influence the infection rate. It seems likely that 
they failed to control the factors that differentiated high and low risk patients 
and this diminished the studies relevance. 
Hinarejos et al.33 performed a well constructed prospective study with 2948 
cemented total knee replacements that were randomised to use the same 
bone cement with or without added erythromycin and colistin. They 
reported no difference (1.4% vs. 1.35 %) in the incidence of deep infection in 
the first year between groups. Their findings do not necessarily conflict with 
the vast majority of the studies included in Parvizi's meta -analysis that used 
gentamicin as the antibiotic. The most logical conclusion is that the 
erythromycin / colistin combination is not as efficacious as gentamicin at 
preventing infection following primary arthroplasty. 
1.1.7. Causative organisms 
The resident micro -flora of human skin consists primarily of Gram -positive 
bacteria, including the genera Staphylococcus, Propionibacterium and 
Corynebacterium. Staphylococcal spp are identified as pathogens in around 
2 / 3rds of infected joint replacements23'39-42 (Table 1.2). Whilst the coagulase 
negative staphylococci that commonly colonise normal immuno- competent 
21 
skin do not normally cause infection, they are frequent opportunistic peri- 
prothetic pathogens. S. lugdunensis is an exception as it is coagulase negative 
but can cause severe soft tissue infection and should be suspected of being 
pathogenic if identified'. 
The coagulase positive Staphylococcus aureus is another opportunistic 
pathogen but only colonizes healthy adults transiently, in the groin or 
axillae, or permanently in the nostrils or in areas of dermatitis`. 
Approximately 45% of S. aureus strains isolated in the UK are methicillin 
resistant (MRSA)45. There are two dominant clones of Epidemic MRSA 
(EMRSA -15 and EMRSA -16) that cause over 90% of all cases in Scotland46 
Propionibacteria are aero- tolerant anaerobes that thrive in the anoxic 
environment of sebaceous glands. They have been identified from as many 
as 62% of hip implants47 often requiring prolonged anaerobic culture before 
identification can be made. Schäfer et aí23. published their clinical series of 
aspirations from PJI and highlighted two important points. The first was 
that the fastidious organisms (such as Propionibacterium and 
Peptostreptococcus spp) accounted for more than 25% of pathogens detected 
but took longer than a week to become apparent. Obviously, these late 
cultures are prone to contamination and so they also correlated their 
microbiological with histological results before considering it an infection. 
Interestingly, they found similar proportion of true positives in the late 
compared to early positive cultures (61% vs. 73% p =ns). 
A commonly cited series of 112 prosthetic joint infections from Oxford48 has 
not been included in Table 1.2, as in that study the definition of infection 
included a single positive culture without histological corroboration which 
would have increased their false positive rate. This was counter to the 
groups previous recommendations that the optimal number of samples is 5 if 











n =85142 % 
CNS 49 54 37 23 40 40.6 
S. aureus 13 11 34 30 19 21.4 
E. coli 7 2 11 6 5 6.2 
Enterococcus 6 5 3 - 6 5 
Propionibacteriurn - 14 8 - 7 9.6 
Streptococcus - 5 7 9 9 7.5 
Other bacteria 25 9 - 32 14 20 
Table 1.2: Causative organisms in prosthetic joint infection. 
Author, study size and relative frequencies ( %) of species isolated. 
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1.1.8. Classification of prosthetic related infection 
One obstacle in improving the outcome after prosthetic related infection is 
the lack of a comprehensive classification system. There are a number of key 
independent variables that need to be matched to enable comparison 
between different studies. These include the chronicity of the infection, the 
virulence and sensitivity of the infecting organism if known, whether the 
prosthesis is currently stable, the hosts ability to mount a strong immune 
response, presence and degree of osteomyelits, quantitate bone loss and 
degree of surrounding soft tissue damage. One can easily envisage, with 
each factor requiring a number of sub -categories, ending up with a 
cumbersome classification system. Even attempts such as McPherson 's in 
200249 to produce simplified systems with three categories: infection 
chronicity, systemic host grade and local extremity grade has not been 
subsequently used in the literature. Therefore attempts at constructing a 
comprehensive system for all musculoskeletal infections including PJI, such 
as the one proposed recently by Romano50 with 7 categories and 33 
subcategories, seems unlikely to be adopted. 
Classifications limited to PJI have been more readily used with modifications 
to the Coventry classification51 by first Tsukajama52 and then Zimmerli' who 
defined acute infections as being present for less than 4 weeks. A description 
of PJI would include information about the source and chronicity of 
infection. The organisms can either be introduced to the joint at the time of 
operation, via haematogenous spread or by contiguous inoculation. The 
chronicity of infection depends upon the source. Therefore, an acute 
infection occurs within 4 weeks postoperatively and delayed infection 
presents within a year. Late infection has to be more than a year 
postoperatively but it treated differently depending if inoculation is peri- 
operative, haematogenous or contiguous. 
24 
1.2. Treatment strategies in prosthetic joint 
infection 
As the bacteria responsible for PJI grow slowly in a sessile biofilm state, in 
which they are recalcitrant to conventional antibiotic therapy, surgical 
management is necessary to affect a cure. The most effective way to treat 
peri- prosthetic infections is to debride all devitalized tissues, remove all the 
prosthetic material, administer appropriate antibiotics and support the host's 
immune system in dealing with the remaining bacteria. This is only easily 
achievable in cases where the prosthesis is easily replaceable (e.g. peripheral 
cannula) or functionally redundant (e.g. metal work around a healed 
fracture). The management of prosthetic joint infection is more complicated 
and necessitates eradicating the infection while preserving mechanical 
function of the joint. Clinicians tend to use a stepwise approach to selecting 
the appropriate surgical treatment (Table 1.3). 
1.2.1. Debridement, Antibiotics and Implant Retention (DAIR) 
Attempts at component revision often can result in reduction of bone stock 
and peri- operative fracture, making subsequent reconstruction more 
challenging. Unsurprisingly surgeons have tried to retain stable implants 
with varying degrees of success. The outcome of DAIR depends heavily on 
the time between infection onset and treatment with between 69 -91% success 
reported in patients with symptoms of less than one month compared to only 
16.6% if present for more than six months' 
The largest series of 112 patients treated with DAIR was an observational 
study over a five year period in Oxford55 . Overall 81% of joints remained in 
situ after 2 years. The majority of patients received both oral ciprofloxacin 
and rifampicin for a mean of 1.5 years. Multivariate analysis indicated that, 
in terms of recurrent infection: arthroscopic debridement was less effective 
than open surgery [HR] 4.2; S. aureus was an independent variable associated 
with failure [HR] 2.9; previously revised 
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Indications 
Symptoms Symptoms for > 3 Poor soft tissues Resistant Patient unfit for 
fors 3 
weeks 
weeks or organism or does not wish 
procedure 
No sinus present 
No sinus present Sinus present Poor host Sensitive to oral 
antibiotic 
Susceptible Susceptible 
Stable implant organism organism V 
Susceptible `I 
organism `I Long -term 
antibiotic 
suppression 2 stage revision 
with longer 
4 
2 stage revision 
with short 
interval of 
interval of 8-16 
weeks 




2- 3weeks Can be left as an 
excision 





Table 1.3: A stepwise approach to selecting a treatment strategy in prosthetic 
joint infection. 
The left hand boxes represents the minimum surgical procedure required for eradication of 
PJI. As the operative indications become less favorable, a more extensive surgical tactic is 
required. Long -term antibiotic suppression is the correct option for a proportion of patients 
but it will not result in a eradication of infection. See glossary for explanation of terms. 
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implants did worse than primary ones [HR] 3.1; patients debrided within 
three days of presentation had after univariate analysis, a [HR] 0.36 
compared to patients who were delayed more than two weeks. The authors 
had made an error in their analysis (by attributing a [HR] of 1 to a shorter 
rather than longer delay in presentation) and had therefore not included this 
in the multi- variant model. 
The Foreign Body -Infection Group published a prospective randomised trial 
comparing rifampicin to placebo when treating staphylococcal prosthetic 
infection treated with DAIR in 1998'6. It remains an extremely influential 
paper with clinicians and represents the only 'A -I' level of recommendation 
in the 175 papers cited in the 2012 'Diagnosis and Management of Prosthetic 
Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society 
of America'20. Scrutiny of the methods however, cast significant doubt on its 
ability to guide treatment of joint infection. It only contained 8 infected 
arthroplasty cases in the final analysis and was poorly case controlled. This 
study however led Zimmerli53 to publish in 2004 what has become the most 
widely used algorithm to deal with infected joint replacements and has 
published a 10 year series with a 91% cure rate after DAIR in appropriately 
selected patients'. 
1.2.2. Single -Stage Revisions 
A single -stage revision is a surgical procedure in which the infected tissues 
and prosthesis are removed, and during the same anaesthetic, a new joint 
replacement is inserted and the wounds closed. It is gaining popularity 
especially in Europe and a review in 2008 of more than 1200 infected joint 
replacements from 12 studies showed that the combined 5 year implant 
survival rate after single stage revision was 83 %57. When its use is strictly 
limited to those patients where a single causative organism is known to be 
susceptible to appropriate antibiotics, there are no sinuses present, the 
patient is immuno- competent and the reconstruction after debridement 
relatively straight forward, the results seem to be even more encouraging. 
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Oussedik et al.'$ selected 11 suitable patients from 50 consecutive infected hip 
replacements and achieved 100% cure at mean of 5 years after a single stage 
revision. The same group have reported 94% 2 -year success with knee 
replacements'. Joulie et a1.60 followed Zimmerli s protocol' and cured 94% of 
their patients after single stage revision of both hip and knee arthroplasty 
that had been infected with S. aureus. 
1.2.3. Two -Stage Revisions 
A two -stage revision differs from a one -stage as the re- implantation is 
performed weeks or months after the ex -plant. It remains the current gold 
standard method of eradicating infection, achieving it in > 90% of patients in 
most published series '. It allows the surgeon two opportunities to debride 
any devitalized tissue, identify the responsible pathogen and reduce the 
bacterial load by several orders of magnitude. The majority of surgeons now 
place an ALAC spacer between stages that helps to preserve a more normal 
soft tissue envelope and deliver very high local concentrations of antibiotics 
with few systemic side effects. 
The clinician can monitor the patients' recovery and chose the most 
appropriate time interval to perform the second re- implantation stage. 
Traditionally, systemic antibiotic have been continued for at least 6 weeks 
before the second stage. This length of time is reputed to allow necrotic bone 
to become resorbed. However there seems little published evidence to 
support the view that an extended course is more efficacious than an 
appropriately selected shorter one. In two multi- centre studies totaling 749 
patients with S. aureus bacteraemia, the duration of anti- staphylococcal 
therapy was not associated with clinical relapse61,62 and both papers found 
that the most important factor was prompt initiation of appropriate 
antibiotics. This is supported by a conclusion from the Oxford DAIR study', 
that an extended course of parenteral antibiotics simply prolonged rather 
than prevented the infection recurring. 
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Stockley et aí.63 reported 88% cure at 2 years after 114 two -stage hip revisions. 
This success rate is comparable to the majority of two -stage revisions in the 
literature however they did not use more than two doses of post operative 
antibiotics and relied exclusively on locally delivered antibiotics from cement 
beads to augment the host innate defenses. When the soft tissues envelope 
was adequate and inflammatory markers were low, the patient was 
considered for a second stage reconstruction. This interval was on average 
6.4 months (2 to 22) and no organism was cultured in 84% of patients at that 
point. They found no association between the cure rate and the infecting 
organism, positive second -stage culture or the number of operations prior to 
their intervention. 
1.2.4. Suppressive antibiotics 
In general, treatment with suppressive antibiotics is considered in patients 
who have contraindications, or do not wish further operative intervention. 
No studies have reported a complete cohort without attempts at 
debridement. However there are subsets within more heterogeneous groups 
that can be examined. 7/24 patients within Trebse et al.64 prospective cohort 
study were treated with combination antibiotic therapy alone and no 
recurrence was reported during the 3 -year follow -up period. Similarly 
Goulet et al.65 reported that the 8 / 19 patients selected not to undergo 
debridement had a greater chance of implant survival at 2 years than the 
patients that were debrided (80 vs. 30 %). They both postulated that this 
difference could be explained by pre -selecting the patients with early 
infections, less aggressive and more sensitive organisms. Although it seems 
suppression is effective in preventing recurrence in the medium term, it will 
not be curative and most patients and surgeons would prefer to attempt a 
curative procedure. 
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1.2.5. Summary of treatment strategies 
By using this step -wise approach (Table 1.3) to treat PJI, clinicians are trying 
to effect eradication of infection whilst maintaining long -term joint function 
and reducing patient morbidity as much as possible. Each different surgical 
option should cure around 85 -90% of patients if they are selected carefully, 
debrided meticulously and appropriate antibiotics administered in a timely 
fashion. 
Consensus about the best class of antibiotic to be given, whether to combine 
them, their mode of delivery and the length of their administration are still 
lacking. The published literature is limited in its generalisability because of a 
number of factors. Approximately 1,500 new patients are treated for PJI each 
year in the UK but they are divided between 183 NHS Trusts and similar 
numbers of private providers1 °'11, each following slightly different local 
protocols. Even if a study could recruit large numbers of patients, then the 
variation within the group of bacterial species, chronicity of infection, host 
type and implant type, would all have to be controlled for before starting to 
compare any treatment modalities. Previous prospective studies have 
demonstrated a 30% drop out rate' and long term follow up is required. 
This kind of multi- centre study is expensive and if not funded centrally, 
could be prone to bias from the pharmaceutical industry. 
There is also likely to be a reporting bias with PJI as registries do not provide 
information about true infection rates. The England and Wales Joint 
Register10 does not record infection as an outcome unless the joint is revised 
and in Scotland11 an infection is not recorded if it presents after a year, 
potentially missing between a third and quarter of all cases'''. The literature 
is also likely to contain publication bias, with most series originating from 
units with an expertise in PJI. It is unlikely that smaller units would be able 
to recruit a cohort large enough to be accepted for publication. It is also 
conceivable that units with poorer results than expected, would be unlikely 
submit their results for peer review. 
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1.3. Staphylococcal biofilm 
A biofilm can be defined as an aggregate of micro- organisms which are 
adherent to a surface, embedded within an extracellular matrix and exhibit 
an altered phenotype with respect to growth rate and gene transcription'. 
Biofilms offer microorganisms more protection from the extreme physical 
and chemical stresses they are exposed to as well as acting as an arena, which 
can facilitate horizontal gene transfer and coordinated gene expression via 
quorum sensing. 
The master lens maker Antonie van Leeuwenhoek was the first to observe a 
biofilm in 1676 through his handcrafted microscope when he examined his 
own dental plaque. William Costerton first coined the term 'biofilm' in 
197867 after he slipped whilst crossing an icy stream in the wilds of British 
Columbia. After examining the slime, he found it was composed of a very 
high density of sessile (Latin for seated) bacteria that greatly outnumbered 
the planktonic (Greek for wandering) bacteria in the same aquatic systems. 
Since then biofilms have been found to be pervasive both in both natural and 
man -made ecosystems. 
They are the predominant ( >95 %) form in which microorganisms exist and 
have been estimated to contain up to 50% of the Earth's biomass68'69. 
Evidence of cyanobacterial biofilms have been found in fossilized 
stromatolites that existed more than 3 billion years ago70 and have been 
isolated from Antarctic ice lakes71, hydrothermal vents', plant roots and 
leaves73, industrial and domestic pipes and dental plaque. Bacterial biofilms 
have been implicated in between 65 -80% of human infection74 and are found 
to grow on native as well as prosthetic surfaces. The scope of this chapter 
will however, now focus specifically on staphylococcal biofilms seen on 
orthopaedic joint replacements. 
Staphylococci are Gram -positive, facultative anaerobic prokaryotes. They 
are spherical with a diameter of 1µm and grow in grape like clusters as they 
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remain attached to their sister cell whilst they divide sequentially in three 
perpendicular planes. More than 40 species of staphylococci have been 
described, and 16S RNA analysis groups them into 11 clusters". The most 
common groups seen clinically in humans is the coagulase positive S. aureus 
and the Coagulase Negative Staphylococci (CNS) (S. epidermidis, S. capitis, S. 
haemolytic, S. hominis, S. lugdunensis, S. saprophytic, S. zvarneri and S. pasteuri). 
CNS are one of the most populous species of the human skin microbiome44. 
Although they are not generally considered pathogenic, they have all have 
been recovered from infected implants76 and S. lugdunensis can cause serious 
soft tissue infection43. S. aureus is considered an opportunistic human 
pathogen, most commonly isolated from the anterior nares or groin, where it 
prefers the higher humidity and temperature. 60% of the population are 
intermittent carriers, with 20% being persistent carriers. Interestingly there 
is evidence that a strain of S. epidermidis that secretes a serine protease (Esp) 
acts synergistically with human antimicrobial peptide f3 active against S. 
aureus. The presence of this protective strain has been epidemiologically 
correlated to the 20% of humans who do not carry S. aureus in their nose'. 
All staphylococci share the same basic ultra- structure that includes a micro - 
capsule, cell wall, and cytoplasmic space containing the unbound DNA, 
plasmids and 70S ribosome (with 30S and 50S subunits). The peptidoglycan 
cell wall is around 50nm thick and is formed from chains of alternating N- 
acetylglucosamine (NAG) and N- acetylmuramic acid (NAM) sugars. They 
are connected by f3- glycosidic bonds to short peptides (L- alanine, D- alanine, 
D- glutamine and L- lysine in S. aureus), to form a lattice structure. Traversing 
through the several layers of these peptidoglycan sheets are negatively 
charged teichoic acids that have a role in intercellular attachment. 
S. aureus biofilm was first visualised in 1982 using electron microscopy to 
examine an infected heart pacing wire79. Since then, staphylococci have been 
recognised as the major cause of device associated infection, isolated in 
around 2 / 3rd5 of all prosthetic joint infections (see Table 1.2). Their ubiquity 
as part of the skin flora explains why they are frequently introduced as 
32 
contaminants, but it is their ability to form stable biofilms, which are tolerant 
to the host's and clinicians attempt to eradicate them, that makes them so 
prevalent in PJI. 
1.3.1. Initial attachment 
When planktonic organisms come into contact with a substratum, they start 
to switch to a sessile phenotype and form a biofilm perhaps as a means of 
surviving the austere environment, ready to colonise new niches when 
conditions allow. Although it is a temporal process, it is frequently 
conceptualised in the 4 stages of initial attachment, cell aggregation, biofilm 
maturation and eventually bacterial detachment (Figure 1.2) 
As an implant is inserted, the host's plasma quickly 'conditions' the 
prosthesis with proteins such as fibrinogen, vitronectin and fibronectin, into 
which the bacteria are absorbed. The extent to which they are absorbed 
depends primarily upon a number of non specific factors including: Van der 
Waals forces, electrostatic interactions and hydrophobic effects with 
biomaterials with hydrophilic 'wettable' surfaces seen to absorb the fewest 
bacteria8°. In addition to this passive process, staphylococci actively secrete a 
variety of protein adhesins in an effort to bind to the substratum. These 
include a variety of Microbial Surface Components Recognising Adhesive 
Matrix Molecules (MSCRAMMs) and Autolysin homologues (Atl and AtL). 
Adhesins have been demonstrated to mediate attachment to polystyrene, 
vibronectin and even facilitate internalization into non -professional 









































































































































































































































































































































































































































































































































1.3.2. Cell aggregation 
Once attached, the bacteria start to aggregate together in layers within 
Extracellular Polymeric Substance (EPS, commonly known as glycocalyx) 
that is composed of secreted polysaccharides, extracellular DNA (eDNA), 
teichoic acids and proteins such as Autolysin associated protein (Aap) 
(Figure 1.3). Interestingly, Aap activation is catalysed by the host's own 
innate response to infection. The proteases secreted by granulocytes cleave 
the Aap precursor stimulting further aggregation and biofilm formation82. 
The most important biofilm associated polysaccharide in staphylococci is 
Polysaccharide Intercellular Adhesin (PIA), a partially N- acetylated glycan 
and is regarded as central to their biofilm formation. The de- acetylated 
portions impart a positive charge to the PIA when it is exposed to acidic 
environments found in wounds and skin. The resulting electrostatic 
attraction between PIA and the negatively charged teichoic acids in the cell 
wall ensure the bacteria are embedded securely within the hydrated 
matrix. The capacity for PIA synthesis is encoded at the intercellular 
adhesion (icaADBC) locus in all staphylococci except S. haemolyticus83 and S. 
saprophytic84 but its absence does not prevent biofilm formation, suggesting 
several ica- independent pathways also play roles85. The ica operon is up- 
regulated in conditions of nutrient depletion, anaerobiosis, low cell 
density, salt stress and ethanol by the global gene regulators SarA and 
alternative sigma factor SigmaB86 (Figure 1.4). The subsequent production 
of PIA facilitates intercellular adhesion and biofilm aggregation, protecting 
the organisms from physical degradation, desiccation, phagocytosis and 
oxidative stresses that polymorphonuclear leucocytes attempt to impartß7. 
1.3.3. Maturation 
The biofilm is seen to mature dynamically over time with spatial re- 
organisation allowing channels to form between pedunculated structures in 
the matrix and supply nutrients to the deeper layers66. The eDNA found 
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within the matrix, originates from lysed bacteria and endows structural 
integrity to this 3 dimensional architecture, as well as possibly enabling 
horizontal gene transfer'. The physical time dependent viscoelastic 
properties of the biofilm matrix allow it to adapt to high shear stresses, 
reducing the rate of cell detachment and preventing the rolling migration 
along a substratum''". 
b8/03/11:1:112:45 BinSEM 3O"t3kV 1;j.5m z4 98k 54(U) 10,Oum ' 
Figure 1.3: Cryo -scanning electron microscopy of biofilm. 
Photograph taken taken by the author, perpendicular to a 20- hour -old S. 
aureus biofilm already aggregated into 4 layers within a self -produced 
Extacellular Polymeric Substance (EPS) (commonly called a glycocalyx). 
1.3.4. Detachment 
The term quorum sensing (QS) is used to describe the phenomenon, seen in a 
wide range of bacteria, of cell density- dependent regulation of gene 
expression. It allows individual staphylococci the opportunity to express 
virulence factors as part of a timely and co- coordinated multi -cellular 
response to changing conditions. In doing so, it improves its odds of 
genomic survival compared to a non co- operative population. Staphylococci 
are known to have two autocrine quorum sensing systems encoded within 
36 
the accessory gene regulator (agr) and LuxS loci respectively. Agr uses RNA 
III as an effector to mediate the expression of amphiphillic peptides (also 
knows as Phenol -Soluble Modulins (PSMs), which act as biofilm detergents91 
(Figure 1.2). Among the many other accessory genes it regulates, Agr also 
down -regulates the expression of surface proteins such as MSCRAMM's 
required for surface binding (Figure 1.4). 
LuxS inhibits ica mediated PIA production92 whilst metabolic slow down, has 
the opposite effect, enhancing PIA biosynthesis and facilitating a sessile state. 
As the biofilm matures and the cell density increases to typically 15% of 
volume, both Agr and LuxS are up- regulated when the threshold 
concentration of autoinducers is reached. In contrast to the extensively 
studied Gram -negative QS systems, staphylococci colonise and form a 
biofilm more readily when bacterial density and QS are at low levels. The 
high levels of QS associated with higher cell density have the net effect of 
causing biofilm detachment. The liberated bacteria may simply migrate a 
short distance along the substratum to increase the biofilms surface area or 
switch back to their more virulent planktonic form and migrate to exploit 
distant sites within the host. 
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Figure 1.4: Outline of genomic regulation during staphylococcal biofilm 
formation. Adapted from Arciola et aí.ß6. 
The agr locus consists of 2 divergent transcription units driven by promoters P2 and 
P3. The P2 operon encodes a 2 component -signaling molecule, of which AgrC is the 
receptor and AgrA is the response regulator. 
Agr also encodes 2 proteins AgrB and D, which combine to produce and secrete an 
Auto Inducing Peptide (AIP) that is a ligand for AgrC. AgrA functions to activate 
transcription from its own promoter and from the argP3 promoter, which drives the 
synthesis of RNAIII, the main effector in the Quorum Sensing system 93. 
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1.4. Persisters, small colony variants and 
biofilm phenotypes 
Although in many clinical bacterial infections, the human host can achieve 
complete resolution, there are numerous examples of when it cannot, even 
when augmented by medical treatments. Common examples include 
Helicobacter pylori induced gastritis, reactivation of latent Mycobacterium 
tuberculosis, Haemophilus influenzae associated with recurrent otitis media and 
prosthetic related infection, such as E. coli urinary catheter mediated sepsis 
and staphylococcal joint infections. 
Over the years, the bacteria responsible for these chronic infections have 
been described in a number of discrete physiological states, that can resist 
eradication. Persisters, Small Colony Variants (SCV) and biofilms are 
generally thought to be distinct phenotypes but through the course of this 
section, the argument that these phenotypes all possibly derive from a 
common intrinsic response to environmental stresses, will be advanced. 
1.4.1. Persisters 
Persisters are small subpopulations of bacteria that can survive prolonged 
exposure to high concentrations of antibiotics without any specific, 
inheritable resistance mechanisms. Persisters are typically very slow 
growing or dormant. They were first described in 1944 by Joseph Bigger 
who reported that a small, but consistent proportion of S. aureus that 
survived exposure to penicillin. Subcultures of these persisters could be 
eradicated however, if exposed to a similar level of penicillin for a second 
time94 
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Balaban et al' explored persistence further with experimental and 
mathematical studies of two strains of E. coli that were high persister (hip) 
mutants that tolerated normally bactericidal concentrations of ampicillin, 
and found two types of co- existing persisters (Figure 1.5). Type I persisters 
were generated primarily during sub -maximal growth conditions (where 
they reach 102) and displayed antibiotic tolerance after exposure to 
significant environmental stresses. Type II persisters are less common 
(around 10 -6) and appear to be generated stochastically throughout the cell 
cycle without an obvious extrinsic stimulus. 
Becoming a persister does not make sense from an individual organism - 
based perspective, as its growth slows or stops and would be quickly out 
replicated by its Normal Colony Phenotype (NCP) sisters. It does make 
sense however if you consider it from the perspective of the whole 
population acting co- operatively towards the continued survival of that 
genome. There appears to be different levels of contingency, with a few 
Type II persisters present at all times in case of a major unforeseen 
environmental catastrophe. If the population becomes stressed, more 
organisms appear to take this as a warning of impending death and become 
Type I persisters but most of the population continues to maximise their 
metabolic and reproductive potential until the bitter end. This hedge 
betting96 ensures the population is maximised if environmental conditions 
are optimal whilst maintaining a genetic reservoir to repopulate from, should 
it become austere for a period. Some doubt does remain as to whether Type 
II persisters are generated without any stimulus or whether that stimulus has 
not been elucidated as yet97. 
1.4.2. Small colony variants 
Small colony variant (SCV) is a descriptive term for an unstable genetic 
mutant, with low replication rate, that differs from the NCP. S. aureus SCV 
for instance are auxotrophic (lacking the ability to produce metabolites 
essential for normal growth) resulting in a defective Electron Transfer Chain 
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(ETC)96. At first glance, this appears to hinder S. aureus, resulting in non- 
pigmented colonies 10 times smaller than NCP and decreasing both the a- 
toxin and coagulase production. However, the ETC suppression also confers 
several survival advantages, such as the ability to reside intra- cellularly, 
display increased adhesion expression and tolerate high concentrations of 
antibiotics through mechanisms that will be discussed in section 1.4.495. SCV 
are a heterogeneous group within themselves with reports of S. aureus 
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Figure 1.5: Bacterial population response to different environmental 
conditions. 
Type II persisters / SCV are unstable genetic mutants generated stochastically 
during the exponential phase possibly as a result of imperfect replication. This is a 
reversible and dynamic phenotypic equilibrium with a prevalence of around one 
per million NCP. Type I persisters are generated as environmental stresses increase 
(such as starvation, antibiotics, hypoxia, oxidative stress, heat stress, envelope stress 
and low pH) with their prevalence depending on the scale and duration of these 
stresses. A supra -MIC concentration of a bactericidal antibiotic is delivered that will 
kill the NCP leaving the persisters to repopulate the niche when conditions permit. 
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In a recent study, 11/31 PJIs were found to be SCV of S. epidermidis but 
despite similar appearances, they varied in their degree of aminoglycoside 
tolerance, type of auxotrophy and enhanced biofilm formation101. SCV have 
been shown to be present at similar concentrations (3x10-6) as type II 
persisters in the stationary phase with the absence of any selective 
pressure102. They seem to be generated as an inevitable natural consequence 
during replication in the exponential phase. The population of SCV is 
dynamic and the bidirectional phenotypic switching seen indicates the 
genetic mutations are generally unstable102. The SCV confers marked 
aminoglyoside tolerance that is lost when the purified SCV cell is sub- 
cultured and re- exposed. This description of the S. aureus SCV seems one 
that bears striking resemblance to the description of type II persisters 
reported by Balaban et al. as well as the original description of persisters by 
Bigger in 194491'95 
Continued selection pressure from high levels of gentamicin, commonly 
encountered around prosthetic joints, would favor the recovery of relatively 
stable SCV /type II persisters that revert back to NCP when that pressure is 
removed and this is commonly seen in clinical practice. SCV's are also 
notorious for their ability to reside intra- cellularly, thereby avoiding extreme 
environmental stresses and antibiotics. This internalisation phenomenon 
appears to be mediated by the autolysins At1A in S. aureus and AltE in S. 
epidermidis, both of which are associated with the initial attachment phase of 
biofilm to a substrate (Figure 1.4). 
1.4.3. Biofilm phenotype 
As previously described, a biofilm is a aggregate of micro -organisms that are 
adherent to a surface, embedded within an extracellular matrix and exhibit 
an altered phenotype66. The physicochemical properties of the extracellular 
matrix confer protection from heat shock, desiccation and phagocytosis. It 
also has been shown to slow but not preclude antibiotic penetration and so 
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cannot fully explain the antibiotic tolerance seen in the biofilm phenotype103 
Numerous studies, in a range of bacteria, have reported mechanisms to 
explain this antibiotic tolerance and include: limitation of nutrients and 
oxygen; reduced growth rates; facultative intracellular growth and a high 
proportion of SCV / persister phenotypes within the biofilm10 
This invites the questions: are these mechanisms responsible for antibiotic 
tolerance interconnected ?i0' Is an in -vivo biofilm simply a manifestation of 
the natural relationship between NCP, SCV and persister phenotypes when a 
suitable substrate for attachment is present? 
1.4.4. How do persisters tolerate antibiotics? 
Thus far, inhibition of protein synthesis' and dissipation of the Proton 
Motive Force (PMF)107 appear to be the main mechanisms underlying 
persister formation. This inhibition of metabolic pathways could be effected 
by genetic mutation102, Toxin -Antitoxin (TA) systems108 or direct inhibition of 
the ribosome by some antibiotics'. All of these result can result in the cell 
displaying multi -drug tolerance and concentrations of up to 1000x the MIC 
of planktonic culture are required to eradicate them in mature biofilm' 
This phenomenon is also seen in planktonic cultures pre- exposed to sub -MIC 
levels of either gentamicin, ciprofloxacin, oxacillin or vancomycin, where it 
induces a multi-drug tolerance that results in higher viable cell densities if re- 
exposed to sub -MIC levels of antibiotics than cultures that were not pre- 
exposed'. 
Although slow growth or dormancy has been shown as insufficient to 
explain the persister phenotype', less replication does reduce the 
availability of active binding sites for the penicillins, glycopeptides and 
quinolones that target the cell wall and DNA. Aminoglyosides uptake into 
the cell is an energy dependent process requiring a threshold cell membrane 
potential of -155mV111 and uptake is proportional to increased PMF. The 
slower metabolic rate of persisters reduces ATP production and the PMF, 
thereby limiting the uptake of aminoglyosides and enabling tolerance of 
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concentrations normally bactericidal to the NCP. Supplementary fructose 
that enters upper glycolysis via the phosphotransferase system and generates 
NADH utilised by the ETC to increase PMF, has been shown to facilitate the 
killing of S. aureus persisters by 2 orders of magnitude compared to 
controls107. Lower metabolites that could only be utilized by the pentose 
phosphate or tri- carboxylic acid pathway did not potentiate 
aminoglycosides. This fructose -enabled killing was found to be independent 
of aerobic conditions (as long as conditions supported the PMF) and was 
seen with aminoglycosides but not penicillins or quinolones. No growth 
resumption was seen within the 4 -hour period tested, however this would 
not be long enough to exclude that the lag phase of growth was still in 
progress. Further in -vivo studies are needed to confirm both the safety and 
efficacy of this promising metabolite enabled eradication. 
The stringent response (in response to amino acid starvation) has been 
shown to up- regulate the anti- oxidant systems112, presumably to prepare for 
the onset of post -exponential catabolism of non -preferred carbon sources 
using the TCA cycle113. If the conditions allow post -exponential growth, then 
hydroxyl radicals are sequentially detoxified, first by Mn superoxide 
dismutase then by peroxidases and catalase. If environmental conditions 
deteriorate further and inhibits the TCA cycle, this will reduce the generation 
of hydroxyl radicals formed during oxidative phosphorylation and perhaps 
act as a signal transduction pathway that favors the persister phenotype113. 
This mitigation against hydroxyl radicals possibly enables the bacteria to 
survive the additional hydroxyl radicals promoted by the effects of 
bactericidal agents'. 
Another possibility that is likely, but remains unproven, is that the quorum 
sensing system influences the frequency of persister formation in 
staphylococci. There is evidence that indole, an organic alkaloid secreted by 
altruistic E. coli persisters acts as a cue, influences the cell envelope and 
oxidative stress response of neighboring NCP cells and so modulates the 
frequency of persister formation115 The closest evidence that this occurs in 
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staphylococci was reported by Butler et al.116 who interpreted the consistently 
low MIC of indole, compared to antibiotics, against 39 staphylococcal strains, 
as a potential therapeutic development. Another interpretation would be 
that indole is a very effective persister generator and that its use in vivo 
would delay rather than cure any infection. 
1.4.5. Do persisters, SCV and biofilms share common molecular 
mechanisms that allow staphylococci to tolerate stress? 
Despite seemingly unique differences, SCV, persister and biofilm phenotypes 
share important similarities that include being stress inducible, 
demonstrating dramatically slower growth rates and marked tolerance to 
antibiotics. All three characteristics invariably present together as antibiotics 
are known to cause an oxidative stress and slow cellular growth, which leads 
to reduced antibiotic efficacy, due to target inactivity. A recent study by 
Orman et a1.117 used fluorescent assays to show that a lack of replication or a 
low metabolic activity was not necessary or sufficient to turn a NCP into a 
persister but simply increased the likelihood that a cell became a persister 
after it was stressed with antibiotics. Similarly, another study inactivated the 
stringent stress response in a Pseudomonas aeruginosa biofilm and found that 
it's inactivation did not change the slow metabolic rate compared to the 
wild -type but did result in the bacteria being much more susceptible to 
antibiotics'. 
1.4.6. Toxin -antitoxin systems 
As well as nutritional limitation, hypoxia, oxidative stress, heat stress, 
envelope stress, low pH, and exposure to sub -MIC concentrations of 
antibiotics have all been shown to elicit a stress response, in a wide range of 
bacteria including staphylococci, through the Toxin -Antitoxin (TA) 
system118,119 TA systems are composed typically of two genes in an operon 
that encode both a protein toxin and its unstable RNA (Type I) or protein 
(type II) anti-toxin that neutralises it. Down -regulation in the expression of 
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the rapidly degradable antitoxin will allow the more stable toxin to act on its 
target, which is typically mRNA. TA systems regulate genes other than their 
own operons, mediate the general stress response, and help direct cells 
toward the formation of biofilm and Type I persisters120. Numerous studies 
have demonstrated that deleting a single TA system does not reduce 
persistence though, due to the redundancy of these systems121. S. aureus has 
at least one Type I and three Type II TA systems122,123, all of which code for 
endoribonucleases. The most studied of these in S. aureus is the mazFsa locus 
for which over -expression was found to result in a growth arrest, although 
the dormant cells were not examined to determine if they were persisters in 
this study'. The ATP -dependent C1pP protease (and its chaperone C1pC) 
serves as the functional unit for the degradation of all known antitoxins in S. 
aureuslzs 
A comprehensive understanding of why heterogeneous phenotypes are 
generated in an isogenic population is still lacking97. There is an emerging 
Persistence as Stuff Happens (PaSH) hypothesis however; that it is simply a 
natural function of replication that confers genomic advantage through the 
hedge betting strategy and so the genes that control their frequency have 
been selected as the organism has evolved. These are now being elucidated 
"10,125 As the cells divide in the exponential phase, by several groups'°2 
imprecise gene expression can create type II persisters / SCV. During the 
stationary phase and in biofilm, environmental stresses mediated through 
the TA systems and possibly the quorum sensing molecule, indole115, may 
generate type I persisters. The greater the degree and period of stress a 
population is exposed to, the greater the proportion of persisters126 that adapt 
to tolerate both the original stress and others including antibiotics'. 
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1.5. Antibiotics used in PJI 
Despite being identified as an important orthopaedic pathogen in 1880 by 
Scottish surgeon Alexander Ogston127, an effective treatment for 
staphylococcal infection remained elusive and it was still associated with an 
80% mortality just 75 years ago128. The development of penicillin, which 
remains one of the most significant advances in medicine, was certainly not a 
sudden breakthrough as one might expect. From its discovery in 1928 
through to a clinically useful form in Oxford took 12 years and earned 
Fleming, Chain and Florey the Nobel Prize for Physiology or Medicine in 
1945129. Although penicillin was initially effective against a wide range of 
staphylococci, resistance mechanisms quickly emerged and by the 1960's, 
strains resistant to both penicillin and the synthetic penicillinase- resistant 
methicillin had become globally prevalent' 
Antibiotics remain an important adjunct to surgical debridement of 
prosthetic infection but need to be used rationally and sparingly to minimise 
the rate at which resistance to them develops. Currently the central tenets of 
this approach are to: first identify the relevant organisms causing the 
infection; determine how sensitive they are to a wide spectrum of antibiotics; 
selecting an antibiotic that is able to be PharmacoKinetically (PK) delivered, 
at a concentration that is PharmacoDynamically (PD) effective whilst 
maintaining an acceptable side -effect profile. 
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The antibiotics commonly used in PJI are listed in Table 1.4. As can be seen, 
many of these antibiotics are derived from naturally products of soil 
bacterial'. There is a growing realisation that the molecules we use as 
antibiotics, are bacterial secondary metabolites. They seem to be used in 
natural eco- systems, to signal, cue or coerce neighboring bacteria in to 
altering their genomic expression132. It follows then, that bacteria are likely to 
have developed systems to respond to these antibiotics and this must be kept 
in mind when trying to eradicate prosthetic infection. It is recognised that 
exposure to sub -inhibitory levels of one antibiotic leads to high level 
tolerance to multiple and dissimilar antibiotics'10 It is feasible that even very 
high concentrations remain sub -inhibitory to the persister phenotype and 
encourage them to maintain their tolerance to a variety of stresseslo2 
1.5.1. Optimal duration of antibiotic treatment 
A recent survey of over 500 clinicians that treat PJI in the USA found that 3 / 4 
to give 6 -8 weeks of antibiotics aimed at eradicating the 
infection, with only 16% switching to oral antibiotics when clinical response 
allowed and 0.4% treating for less than 4 weeks133. This dogmatic approach 
is repeated in the recent Clinical Practice Guidelines by the Infectious 
Diseases Society of America20 without any evidence cited to justify it except 
expert opinion. The arbitrary 6 weeks is likely to be based on a series of 
animal models in the 1970's and 80's which demonstrated that their bones re- 
vascularised within 3 -4 weeks of surgery134, and historical reports of shorter 
duration failures in cases of acute osteomyelitis in children. Important 
differences between these models and adult PJI exist, which make a 
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Table 1.4: Antibiotics commonly used to treat staphylococcal infections. 
Adapted from Kohanski et al. 
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The systematic reviews136,137 on this subject, conclude that longer courses of 
antibiotic expose the patient to more side effects, whilst there is no clinical 
evidence to suggest they are more effective than a shorter course. Another 
key point can be extrapolated from a prospective cohort of patients with 
chronic osteomyelitis from Oxford's; All 50 patients were treated with 
debridement followed by 6 weeks IV and 6 weeks oral antibiotics. 14 / 35 
infections recurred within a year where the margin of normal bone 
surrounding the resection was less than 5mm, whereas all of the 15 patients 
with adequate resection remained infection free. This emphasises the 
importance of adequate surgical debridement when treating PJI. 
1.5.2. Pharmodynamics of antibiotics 
Antibiotics are broadly classified as either bactericidal or bacteriostatic 
depending on whether they cause cell death or a reversible antagonism to 
cell metabolism. In general if the Minimum Bactericidal Concentration 
(MBC) is equal to or less than 4 times the Minimum Inhibitory Concentration 
(MIC), the antibiotic is designated bactericidal. This distinction is blurred 
somewhat depending on phenotype and what 
oxidative state is present. For example, rifampicin demonstrates more 
bactericidal effect when the balance between the cells' superoxide dismutase 
and free radicals are tipped toward the rifampicin being oxidized, where 
upon it directly damages the DNA when combined in its RNA polymerase 
complex139 -141, rather than just blocking protein transcription. Bacteriostatic 
antibiotics only work if the host immune system can use the bacterial stasis 
as an opportunity to mount an effective response and eradicate the bacteria. 
If the response if ineffective and the antibiotics are stopped then bacterial 
virulence resumes. 
Antibiotics can also be classed as being either concentration dependent, or 
time dependent, depending on the rate and proportion of the population 
they kill (Figure 1.6). Examples of concentration dependent antibiotics 
include the aminoglycosides, daptomycin and fluoroquinolones and so the 
relationship between their peak concentrations and minimum bactericidal 
SO 
concentrations should be an indicator of outcome. Time dependent 
antibiotics include vancomycin, beta -lactams, macrolides, clindamycin, 
tetracyclines and carbapenems. Higher concentrations have no additional 
effect so it is thought vital to deliver a supra -inhibitory concentration over as 
much of the day as possible. A post antibiotic effect is one where growth 
suppression is seen after antibiotic levels have dropped to below MIC and is 
seen with aminoglycosides, fluoroquinolones and rifampicin. 
The 3 most common PK -PD measures are: the duration of time a drug 
concentration remains above the MIC (T >MIC); the ratio of the maximal drug 
concentration to the MIC (Cmax : MIC); the ratio of the Area Under the Curve 
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Figure 1.6: Pharmodynamic profile of commonly used 
Reproduced with permission from Rybak MJ Am. J. Med. 
concentration, AUC - area under curve, MIC = minimum 
PAE = post antibiotic effect, T = time. 
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antibiotic in PJI. 
2006143. Cmax= Maximum 
inhibitory concentration, 
1.5.3. Pharmokinetics of antibiotic delivery 
The concentration of active antibiotic actually present at the site of infection 
depends on the pharmokinetic variables of absorption, distribution, 
metabolism and excretion. Delivering antibiotics to the site of infection can 
be achieved by local administration at the time of surgery, or systemically via 
an oral or parenteral intravenous (IV) route. 100% absorption is seen after IV 
administration but excellent bioavailability can also be achieved using oral 
fluoroquinolone or rifampicin' or when using locally administered 
antibiotics. Active drug availability is increased by low plasma binding, 
good vascularity to the infected area, lipophilic antibiotics with small 
molecular size, favourable pH and ionisation. 
The majority of antibiotics are primarily metabolised in the liver and so the 
proportion of oral dose absorbed is then subject to entero- hepatic metabolism 
before reaching its intended target. Intravenous administration avoids this 
first -pass metabolism but is then subject to metabolism when in the arterial 
circulation and so repeat dosing is needed to maintain supra -inhibitory 
concentrations. Excretion of antibiotics is primarily renal and so systemic 
dosage must be reduced if renal impairment is present to avoid 
nephrotoxicity. Only a very small proportion of locally administered 
antibiotic enters the systemic circulation145 and so it is only minimally 
affected by hepatic metabolism or renal excretion. Although systemic 
administration has the advantage of treating many sites at once it may lead 
to unforeseen consequences to the microbiome such as precipitation of 
Clostridium difficile infection', although the incidence in patients undergoing 
primary arthroplasty is extremely low (1.7 cases per 1000)147 
Even with adequate serum levels, antibiotic concentration in bone can be 
suboptimal. Landersdorfer et al.148 reviewed the literature and found the 
mean bone / serum ratios were typically between 0.2 -0.5 after systemic 
administration. They noted substantial heterogeneity in the methods and 
reporting standards and therefore saw large variance in the data sets. In 
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general however, the penicillins and cephalosporins penetrated bone least 
effectively followed in ascending order by glycopeptides, aminoglycosides, 
rifampicin, clindamycin, linezolid, quinolones, tetracyclines. Macrolides 
were found to be the most effective bone penetrators with serum to bone 
ratios of around 1. 
Further complicating this situation is that intracellular persisters are known 
to be prevalent in staphylococcal biofilm infections and appreciation of this 
cellular level of pharmokinetics is perhaps one of the reasons many in vitro 
model are not predictive of in -vivo efficacy. Most antibiotics simply diffuse 
across cell membranes and so smaller lipophilic molecules such as 
daptomycin and quinolones penetrate more readily and accumulate in the 
cytoplasm149 Polar molecules, such as aminoglyosides and glycopeptides 
cannot diffuse readily, and rely upon non -specific endocytosis to enter the 
cell where they accumulate and can act on the persisters that also reside 
within this lysosomal compartment within human cells15o The cytoplasmic 
activity of these polar molecules is limited however, which may have clinical 
significance when treating SCV. 
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1.6. Systemic administration of antibiotics 
1.6.1. Parenteral delivery 
Invariably, intravenous antibiotics are used during the peri- operative period 
as entrai absorption is initially unpredictable and as the IV route delivers 
100% bio- availability it can achieve much higher serum levels. Effective 
doses of gentamicin, vancomycin and daptomycin can only be achieved 
using the parenteral route. 
Gentamicin is typically given once daily at 7mg /kg. Its half -life of 2 hours is 
increased with renal impairment. Target serum levels need to be carefully 
titrated, aiming for peak levels of between 5 -10mg / L to ensure trough levels 
are <1mg /L to avoid renal and vestibular damage. Vancomycin reaches its 
Cmax of around 50mg /L within an hour of infusion, has a half life of 8 hours 
and a target trough level of between 15 -20mg / L for PJI151. Daptomycin, like 
gentamicin and ciprofloxacin, displays concentration dependent killing with 
a Cmax of 94mg / L after once daily 6mg /kg dosing'. Its half -life is 8 hours, it 
is highly protein bound and renally excreted. Initial side effects of myopathy 
were overcome by moving to the once daily dosing regime. It has been 
demonstrated to be safe to use for 6 weeks in patients with PJI153 However 
it has shown mixed efficacy when studied in both animal and human 
populations154 
Flucloxacillin is commonly used to treat sensitive staphylococci, as it is 
rapidly bactericidal and has a favourable side effect profile. It is also an 
example of an antibiotic with much higher serum concentrations after IV 
rather than oral administration. Its Cmax after 2g infusion reaches 244mg / L 
whilst 500mg oral administration only achieves 14.5mg /L. Although 
penicillins have a time -dependent bactericidal action, this difference in the 
Cmax may still be important, as only a small proportion of the serum level is 
seen in bone and it does not accumulate intra- cellularly in humans to any 
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substantial level. Theoretically therefore, higher serum concentrations are 
needed if it is to be effective in treating PJI. 
1.6.2. Entral delivery 
The oral route is the most convenient but can be associated with poor 
outpatient compliance and variations in pharmokinetic profiles between 
patients. Rifampicin is a good example of this, as its serum level is 
dependent upon entero- hepatic recirculation as well as renal and hepatic 
metabolism. This means that if it taken with food, less is resorbed and serum 
levels drop. If 300mg is taken on an empty stomach, the peak of 4mg/L is 
reached within 2 hours and the trough at 12 hours would be around 
0.25mg/L155, still above the expected MIC for staphylococci'''. Rifampicin is 
reputed to be most useful in eradicating intracellular organisms as it 
accumulates up to 10 times more in the host lysosomes than their serum and 
helps overcome the local granulocyte defect that allows the bacteria to reside 
unchecked'. This tendency however, is not exclusive to rifampicin and most 
other classes of antibiotics, apart from penicillin and linezolid, are seen to do 
this15o Rifampicin should not be used as a single agent as resistance quickly 
develops especially if there is still a high bacterial load or inadequate dosing 
established'. 
Clindamycin is strongly plasma bound, hepatically metabolised and has a 
half -life of 2 hours. A French study of 50 patients with osteomyelitis15ß 
demonstrated oral clindamycin had 87% bio- availability, good soft tissue 
penetration, with no significant difference seen in the serum concentration at 
8 hours compared to IV administration (2mg /L). Similarly an oral dose of 
750mg ciprofloxacin has equivalent Cmax (3.6mg / L) and AUC (32mg / hr / L) 
to 400 -mg IV dose159 Linezolid has 100% bioavailability, and after an hour 
following a 600mg oral dose, reaches Cmax of around 20 mg /L. It is only 31% 
plasma protein bound and so is predictably distributed and its trough level is 
around 4mg/L at 12 hours16o 
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1.7. Local administration of antibiotics 
Advantages of treating PJI surgically include debridement of devitalised 
tissues, reduction of bacterial load and affording the surgeon a chance to 
administer antibiotics locally. This depot is not dependent on the presence of 
vascularized tissues, it achieves concentrations that are orders of magnitude 
higher than systemic administration would be able to be safely deliver and 
avoids unwanted antimicrobial effects at distant sites. However, there is a 
possibility that the delivery material may eventually act as an additional 
nidus for infection should it persist after the depot runs out. Biodegradable 
systems such as hydroxyapatite crystals161, bone grafts, collagen sheets162, 
polylactide polymers163 and hyaluronic acid gels164 have all been developed 
as carriers. However Antibiotic Loaded Acrylic bone Cement (ALAC) 
remains the gold standard. Despite systematic reviews focused on the last 40 
years of research in this field, no consensus yet exists as to the optimal 
carrier, its form or the class and dose of antimicrobial it should carry161,165,166_ 
1.7.1. Antibiotic loaded acrylic bone cement (ALAC) 
PolyMethylMethAcrylate (PMMA) acrylic bone cement is the most widely 
used antibiotic carrier in PJI since its introduction in 1970167. It can be 
molded into beads to fill dead space temporarily, contoured as an 
articulating joint spacer, or be used as the interface between the hosts' bone 
and revision joint replacements. There has been numerous in vitro studies 
quantifying and attempting to optimise the concentration of antibiotics 
eluted from PMMA. However due to marked differences in study design, 
drawing conclusions during systematic reviews has been difficult168 -170 
That said, there is a consensus that there is a typical biphasic release seen171, 
with the high initial elution rate primarily a function of surface roughness 
and the prolonged, lower elution rate dependent on the porosity of the 
cement172. The initial rate of elution is approximately 60 µg / cm2 in the first 
hour followed by 5 -10 µg / cm2 / hr over the next 12 hoursl7z-17s 
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The effective concentration of antibiotic will depend on the volume of the 
compartment (V) that the cement surface area (A) elutes into. Typical 
estimates of surface area in a primary arthroplasty are in the region of 150cm2 
and 15mm3 of volume yielding an AV ratio of 10 cm'. Most in -vitro models 
have a very low A /V ratio of between 0.001 to 0.3176 and therefore antibiotic 
concentrations in the first week average around 10 mg / L172. Wang et al.177 
introduced the concept of interfacial gap between the cement and the 
prosthesis (Figure 1.7). In a porcine model they demonstrated that there was 
a 50 -500µm gap along 15% of the interfacial circumference, leading to an 
A /V ratio of around 100. The concentration of gentamicin eluted from 
ALAC with 1.7 % wt /wt was measured using an immunoassay in an in -vitro 
model with similar A /V ratio. It was found to be between 2500 -4000 mg/1,178 
which correlates more closely with previous human in -vivo studies that 
found the average 24 hour peri- prosthetic concentration to be around 150 
mg/L173. 
The difference between these two concentrations might be explained by 
antibiotic diffusing out of the peri- articular compartment into surrounding 
tissues. This concept of concentration gradient is supported by previous 
canine models of infection179, which found a linear relationship between the 
antibiotic concentration in bone and the distance from the intra- medullary 
antibiotic loaded PMMA beads (Figure 1.8). The highest levels were found at 
the endosteal surface and lowest in the periosteum, both peaking from 1 -2 
weeks after implantation. 
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Figure 1.7: Interfacial gap between cement and prosthesis 
Cross -section of porcine femur with prosthesis, ALAC, endosteal bone and cortical 
bone concentrically arranged. The magnified view on the right demonstrates the 
small gap that exists between the cement and prosthesis. A similar gap exists 
between the cement and the bone (not shown) and is due to the volume reduction 
seen as the cement polymerises during curing. 
Figure reproduced from Wang et aI. Interface gap after implantation of a cemented 
femoral stem in pigs. Acta Orthop Scand 70, 234-2391999177. 
Figure 1.8: Appearance of ALAC beads. 
Typically connected together with steel wire. Figure reproduced from18° 
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1.7.2. Optimising ALAC composition 
The addition of an antibiotic powder or liquid to PMMA is deleterious to its 
optimal mechanical properties. If the ALAC is going to be used in a single or 
2' of two -stage revision, then it is expected to also provide long -term 
structural support to the construct. These mechanical characteristics can 
either be measured statically in accordance with ISO 5833 standards'', or 
using the more physiological fatigue testing method. Up to 13% antibiotic 
/ PMMA powder can be added before the ISO standard is breached'82,183 but 
significant differences are seen in the fatigue tests still with as little as 2.5% 
antibiotic per weight1''. This leaves the surgeon scope to balance the risk 
between recurrent infection and long -term stability and vary the amount of 
antibiotic added between 1g and 5.2g of antibiotic per 40g of PMMA. 
Vacuum mixing the ALAC improves its mechanical characteristics by 
reducing its porosity 
the ALAC is not required for support, then attempts to maximize elution 
takes president. as or an additional 
antibiotic has the effect of increasing porosity and so facilitate a higher 
release'. Therefore optimal elution characteristics from PMMA can be seen 
strings of ALAC beads (Figure 1.8) , which have the highest surface area, can 
have high porosity and very high antibiotic/ cement ratios. If temporary 
mechanical support is needed, surgeon can also choose to produce an 
articulating ALAC spacer, which although also can have favorable porosity 
and antibiotic ratios, their shape presents a diminished surface area to mass 
ratio (130 cm2 vs. 160cm2 per 40 beads186) 
Certain antibiotics have historically been thought of as heat unstable during 
the exothermic polymerisation of PMMA which reaches 56 °C for around 3 
minutes's','ss. Studies initially found penicillin isotopes eluted into bone very 
well19 . However a bioassay method concluded they were not functional'', 
although this has recently been contradicted by a study that demonstrated 
bactericidal concentration of oxacillin were eluted for the first 2 days 
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following TKR190 Also, whilst tetracyclines were initially felt to be inactive, 
more recent studies has shown that after heating, around 70% of the 
compound remained active191 so should not be completely discounted from 
further study designs. Chloramphenicol does seem to degrade 
significantly188,192 and rifampicin delays the polymerisation to such an extent 
as to render its addition impractical'''. 
The discussion will now focus on in -vivo models and clinical series of the 
more commonly used techniques to deliver antibiotics in PJI. Differences in 
the many delivery devices, antibiotics added, study duration, measurement 
techniques, and a number of other factors that make comparison infeasible. 
Therefore the discussion is split into techniques used in one stage revision 
and two stage revisions such as beads and spacers. 
13.3. Techniques used in one stage revisions 
As discussed previously, between 1 and 5.2g of antibiotic can be added to 
each 40g mix of PMMA powder before catastrophic mechanical 
consequences are likely. Wahlig et al.195 recorded the gentamicin 
concentrations from surgical drains adjacent to 27 primary hip replacements 
using bioassay. They found a mean gentamicin concentration of 118mg / L 
(range 56 -307mg / L) during the first postoperative day, for the group with 1g 
antibiotic/ 40g PMMA powder. They also noted peak serum levels to range 
between 0.96 and 2.9 mg /L, well below toxic levels for gentamicin. 17mg / L 
of vancomycin has been recorded in the knee joint at 8 hours using HPLC 
following the addition of 1g/40g PMMA. 
A French group196 investigated vancomycin loaded PMMA (1.3g/40g 
PMMA) in both primary joint replacements and a sheep model. They found 
peak drain levels of around 25mg / L at day 1 which tailed off to 1 mg / L by 
day 5. They found the endosteal bone level to peak somewhere between 1 -14 
days at a level of around 50mg /kg bone. The gradient between endosteal 
and outer cortex (Figure 1.7) equilibrated by 3 months with a tissue 
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concentration of 50mg / kg maintained up to 6 months when it tailed off 
sharply. Surprisingly, only non -peer reviewed literature examining the in- 
vivo elution of non -aminoglyoside antibiotics from mechanically stable 
cement mantles was found197 
There have been also been several studies utilising biodegradable delivery 
systems suitable for one stage revisions. Cancellous bone graft mixed with 
vancomycin have been shown to be effective in delivering around 400mg / L 
for the first day and tailing off to elute nearly all of the added antibiotic by 2 
weeks without interfering with graft incorporation, with a dose of 1g 
vancomycin per 300g of bone198. The intra- articular application of gentamicin 
impregnated collagen fleeces has been examined using a canine knee 
model199. They found peak gentamicin levels of 2397mg/L at 80 minutes 
with corresponding serum concentrations of 8mg /L. 
These very high concentrations fall within the mid -range of other published 
in -vivo studies on biodegradable collagen fleeces'', unfortunately 
gentamicin is the only commercially available option at present. 
Biodegradable alginate beads have been used to deliver vancomycin at a 
dose of 154mg / L on day 1, tailing off to 1mg / L at day 28 in a rabbit model'. 
Biodegradable calcium sulphate beads have recently been re- introduced onto 
the market201 and although it's very high zero order elution rate and wide 
variety of possible antimicrobial combinations are attractive, clinical 
evidence of its efficacy is still lacking. 
t7.4. Techniques used in two stage revisions 
Strings of ALAC beads are used to fill dead space and offer an increased 
surface area to elute from. Beads do not provide mechanical integrity and so 
surgeons have been tending to use an anatomically molded temporary 
spacer between revision stages that allows the patient to ambulate better. 
Anagnostakos et al.186 compared the concentration of antibiotics in drain fluid 
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in patients who had either beads or spacers inserted at the end of a first stage 
revision. Both groups had 0.5g of gentamicin and 2g vancomycin per 40g 
PM IA powder. They found the beads eluted more than 3 times more 
antibiotic with peak concentrations seen in day 1; 116mg / L gentamicin and 
80mg / L of vancomycin was eluted from the beads vs 21 and 37mg / L from 
the spacer when analysed using fluorescence polarization immunoassay. 
A well performed in -vivo model which implanted 5 highly antibiotic loaded 
PMMA beads into canine tibia, measured the seroma concentration on day 1 
using a bioassay'. They found peak levels of 7.5mg / L ciprofloxacin, 
1516mg / L clindamycin, l lmg / L vancomycin and 154mg / L of tobramycin. 
Interestingly only vancomycin and clindamycin achieved high levels in bone 
at 28 days (15 and 30mg /L). A different organism was used to bioassay 
clindamycin and this, coupled with the fact that they found the in vitro 
elution of clindamycin, similar to most of the antibiotics tested, should call its 
very high in vivo concentration into question. 
In a rat model, treating osteomyelitis with 7.5% ALAC beads, Rouse et al. 
demonstrated peak bone levels on day four for daptomycin at 178mg /kg and 
49mg /kg for vancomycin182. The first case report of daptomycin being 
incorporated in human ALAC spacer was in 20132 and used 2g gentamicin 
and 2g daptomycin per 40g PMMA powder. The spacer was in situ for 6 
months and no adverse effects (e.g. myositis, rhabdomyolysis, peripheral 
neuropathy, derangement of liver function) were noted. Although linezolid 
has been tested extensively in -vitro and displays reasonable elution 
characteristics''', no in -vivo studies have confirmed this yet. 
Only a few studies have investigated whether spacers retain their biological 
activity throughout their lifespan. Fink et al.' analysed the soft tissue 
specimens that had been adjacent to antibiotic loaded spacers in 14 patients. 
They noted that tissue concentrations ranged widely, but found median 
levels of 10, 60 and 40 mg/kg for gentamicin, clindamycin and vancomycin 
respectively at 6 weeks. 
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1.7.5. Potential adverse effects of local antibiotics 
There have been a handful of case reports of acute renal failure in patients 
with articulating spacers in situ. No other obvious causes were identified 
except an aminoglycoside level of 5mg /L166. That said Evans et al. 63 used 4 g 
of vancomycin and 4.6 g of tobramycin per 40g of PMMA in their spacers. 
All 44 patients were without renal, vestibular, or auditory effects at a 
minimum of 2 years. After single stage revision using a commercial ALAC, a 
maximum plasma concentration of 0.2mg /L gentamicin at 6 hours and 0.1 
mg /L vancomycin at 20 hours was seen, well below toxic levels. A possible 
explanation for this discrepancy could be due to the cyclic loading that the 
articulating spacers are subjected to. Propagation of fatigue fractures could 
expose seams of interior antibiotic that would not normally be eluted so 
rapidly 206 
1.8. Combining antibiotics 
Combining antibiotics both systemically and locally is common clinical 
practice and has been shown to result in the lowest infection rate after 
primary arthoplasty 207. In the context of established infection, it is done for a 
number of theoretical reasons including: broadening the spectrum of 
antibiotic activity in empirical therapy; utilising synergistic effects of 
combinations, preventing resistance mechanisms evolving; enhancing 
intracellular penetration and to limit bacterial toxin and other virulence 
factor expression. Although clindamycin is a bacteriostatic agent it displays 
superior clinical outcomes compared to penicillin in severe streptococcal and 
staphylococcal infection. It does not kill the organisms but does limit the 
production of their virulence factors by blocking peptide translocation at the 
50S ribosome208. In some situations, rapid bacteriolysis has been shown to be 
detrimental to the host as well as the bacterial population209. 
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The influential Swiss infection group led by Zimmerli210 do not recommend 
adding rifampicin until the bacterial load has been lowered, perhaps 2 weeks 
after debridement, in order to reduce the risk of resistance emerging . They 
cite the high intracellular concentration as important to its clinical efficacy. 
Apart from their group's randomised control trial" which has been critiqued 
earlier in this introduction, there has been a dearth of well -designed clinical 
studies and this has led to a significant citation bias in the literature. 
A 2008 systematic review into the adjunctive use of rifampicin for the 
treatment of S. aureus infection211 noted that in vitro results of interactions 
between rifampicin and other antibiotics were heavily method dependent 
and often did not correlate with in -vivo findings. They concluded that 
although adjunctive rifampicin in PJI seemed promising they cautioned that 
more definitive data are lacking. 
It is theorised that the ß- lactams, daptomycin and vancomycin can yield 
synergistic effects by opening pores in the cell wall and facilitate access of the 
fluoroquinolone and aminoglycosides to their target sites within the 
bacteria'. Although this has been demonstrated in a few animal models 
there is no good clinical evidence to suggest dual therapy improves clinical 
outcome in established staphylococcal infection'. Antagonism was also 
commonly noted in many of the in -vitro studies on rifampicin combinations 
which were comprehensive reviewed by Forrest et al.'. This antagonism has 
been replicated in a study of 42 patients treated for MRSA endocarditis in 
which the addition of rifampicin to vancomycin was associated with 
clinically and significant prolongation of bacteraemia214. 
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1.8.1. Future approaches 
As our understanding of staphylococcal metabolism and the mechanisms 
underpinning its pathogenesis has increased, new targets and strategies to 
exert more control over them have been identifieds6'21s These include 
manipulating the agr locus216 and quorum sensing systems217 , which are key 
to the expression of biofilm phenotype, producing bio- materials coated with 
antimicrobial substances218,219 and engineering naturally occurring 
bacteriophages to become more efficient bactericidal agents'. Another 
promising strategy is metabolite- enabled eradication107 in which persisters 
are coaxed into generating a proton -motive force, facilitating aminoglycoside 
uptake and death, without fully reactivating the bacteria into a NCV. 
Intriguingly, persister theory has recently utilised the concept of resonant 
activation more familiar to physicists. This describes an effect seen in 
systems with multiple steady states, in which larger fluctuations in the 
oscillating perturbation, leads to a faster transition rate to a new steady state. 
In the context of PJI, the inherent biological noise within the bacterial toxin - 
antitoxin systems could explain and drive the stochastic transit between the 
normal colony and persister phenotypes. By inducing resonant activation 
one could potentially prompt a fast and synchronized phenotypic switch 
back to a less antibiotic tolerant state221. This may turn out to be the 
mechanism for the intermittent sterilisation effect that Bigger described back 
in 194494 with penicillin and staphylococci but a more complete 
understanding of this process is needed before safe clinical implementation. 
All of these approaches are still years away from clinical trials and there 
remains an urgent clinical need to optimise the current treatment of 
staphylococcal PJI by establishing the most efficacious antimicrobial regime 
to complement surgical debridement. 
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1.9. In vitro biofilm models 
Although in -vitro biofilm assays frequently do not correlate well with clinical 
outcomes, they are a vital first step before animal or human models can be 
justified. The choice of which of the numerous biofilm models would be the 
best is dependent upon the clinical question requiring to be answered, which 
is: 
"Which antibiotic combination delivered immediately after surgical 
debridement, is the most effective at eradicating the patches of 
staphylococcal biofilm that remain ?" 
To answer this question, several aspects in the design of a relevant in -vitro 
biofilm model had to be resolved: selection of a suitable device for generating 
and testing the biofilms; selection of appropriate growth conditions; 
definition of which end -points should be used to analyse the results; 
rationalising which antibiotics should be used and for how long. 
1.9.1. Current biofilm devices 
Several established and reliable biofilm models, summarised very well by 
McBain22`, such as constant depth film fermentors; rotating reactors; perfused 
membrane models; drip flow biofilm reactors; and flow cells were 
considered and discounted as they lacked sufficient throughput to allow the 
estimated 1200 samples to be processed in the time available. Simple agar 
plate methods have been used previously but are not suitable as they use the 
substratum as the source of nutrition, expose the biofilm to air and are 
influenced by differing rates of antibiotic diffusion throughout the agar 
medium. This left 3 suitable models: the submerged substratum, the multi- 
well plate and the modified Robbins device (MRD). 
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1.9.2. Correlating study end points with current clinical practice 
The next decision was how to calculate the viability of the organisms after 
treatments. Groups have used a colorimetric redox marker such as Alamar 
blue225 to indicate metabolic activity or simply optical density of the 
recovered samples, as a proxy for cell death. Attempts were made to stay as 
close to the validated MBECTM protocol as possible to facilitate comparison of 
the results. Ceri et al.109, felt as we did, that the gold standard for 
quantification of viability was extended culture on agar. Not only could the 
bacteria liberated from the biofilm be accurately enumerated, one could 
make comparisons to standard laboratory tests on planktonic cultures. 
Currently, microbiologists determine the Minimum Inhibitory Concentration 
(MIC) of an antibiotic that inhibits growth in a planktonic culture by either 
the ISO 20776 -1 broth micro- dilution or disc diffusion method'. 
Microbiologists then interpret this MIC using a discriminating breakpoint 
concentration, which reflect the drugs bioavailability and previous clinical 
outcome data, thereby defining isolates as susceptible, intermediate or 
resistant. The breakpoints recommended by the British Society for 
Antimicrobial Chemotherapy (BSAC) Working Party, have recently been 
brought into line with the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) guidelines226. In the USA, the Clinical 
Laboratory Standards Institute (CLSI) publishes such guidance and typically 
suggests slightly higher breakpoints. 
The BSAC breakpoint is calculated as (Cmax* F / TE) *S. 
Cmax is the maximum concentration of antibiotic at site of the infection; 
E is a factor by which the breakpoint should exceed MIC (usually 4) 
T is the 1/2 life (2 if <1hr, 0.5 if >3hrs); 
F is a serum binding factor (1 if <70 %, 0.2 if >90 %); 
S is the shift needed to allow for resistant mutants in sensitive strains. 
Typically the resistant breakpoint is set around the Cmax and the sensitive 
breakpoint around 1 / 4 Cmax. Staphylococcal spp. are deemed resistant if the 
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MIC is > 0.5 for clindamycin or rifampicin; > 1 for gentarnicin, ciprofloxacin 
or daptomycin; > 2 for vancomycin; and > 4 for linezolid22'. 
Using breakpoints to interpret MIC's fails in a number of ways in the context 
of PJI. By utilising local delivery of antibiotics at the time of surgery, the Cmax 
is potentially increased by orders of magnitude. Therefore, if this 
susceptibility test is to be used, there is a need to develop higher breakpoints 
to reflect this. It also fails to consider that the biofilm will already be well 
established with a high bacterial load before clinical symptoms manifest 
themselves. Merely inhibiting further growth will only temporarily suppress 
the infection and fail to eradicate it unless the bacterial load is sufficiently 
diminished to allow the host's innate immune system to deal with it. 
Therefore the concentration of antibiotic needed to eradicate the infection 
would be a better measure than MIC. 
1.9.3. Selection of a study end point 
As outlined, the bacteria associated with PJI are in a biofilm rather than a 
planktonic state. It is well known that, even in the absence of specific 
antibiotic resistance factors, organisms in biofilm are generally between 100 - 
1000 times more tolerant to antibiotics than when they revert back into their 
actively growing planktonic state109,228,229 
The Minimal Biofilm Inhibitory Concentration (MBIC) is the lowest 
concentration of antimicrobial that prevents biofilm re- growth. However it 
varies between a 50 -75% reduction of metabolic activity compared to controls 
and has not been extensively established as a concept230,231 The Minimum 
Biofilm Eradication Concentration (MBEC) is more widely recognised and is 
defined as the lowest concentration of antimicrobial that eradicates 99.9% of 
the bacteria compared to growth controls'o9,23z This reduction has not been 
shown to assure that the residual infection can be dealt with by the innate 
immune system but provides the closest approximation to expected in -vivo 
effects. Thus, MBEC was selected as the primary end point of the study. 
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1.9.4. Selection of antibiotics 
A pragmatic approach prompts the selection of the most commonly used 
antibiotics in ALAC (gentamicin, vancomycin, clindamycin, ciprofloxacin 
and rifampicin) as well as reflecting the emerging use daptomycin and 
linezolid. They should be tested both in isolation and in combination at 
physiological doses. Studies have shown that this will vary between 
4000mg / L and 10mg / L in a time and compartment volume dependent 
fashion (section 1.7). The length of antibiotic exposure for this in -vitro model 
was chosen to be 3 hours on the basis of several factors. Firstly, the highest 
and most predictable concentrations will be in the initial few hours following 
administration. Previous work has shown that, of all total gentamicin 
released in the first three days from ALAC, 2/ 3 of it elutes in the first three 
hours174. Secondly, the initial few hours offer the best opportunity to 
eradicate the infection as the biofilm has just been physically debrided and in 
most instances, will not be under preceding antibiotic stress. Thirdly, three 
hours has previously been demonstrated to be long enough to reveal 
persister frequency in previous models using rich media233. Finally, a shorter 
challenge time allowed more samples to be processed in a working 
laboratory week, expanding the choice of which type of biofilm model could 
be used. 
1.9.5. Selection of an alginate biofilm model 
One of the parameters we were keen to change from the MBECTM method 
was biofilm disruption. Previous groups have scraped of the biofilms 4, but 
this has shown to be inferior to sonicating the biofilms away from the 
substratum, resulting in substantial assay variance235 Although sonication 
does not seem to affect the viability of staphylococci (which is protected by 
its cell wall and spherical shape), it does significantly reduce viability of 
Gram negative and anaerobic bacteria'''. In an effort to make this new 
biofilm assay universally applicable, we sought to design a system that 
liberated the biofilm from the substratum without sonication. After 
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literature review a method initially used for cellular immobilisation237 was 
adapted to provide a suitable substratum. A French group had shown that 
sodium alginate could be chelated and then dissolved (using a citric acid and 
sodium carbonate solution) to liberate the immobilised bacteria without 
affecting their viability'''. 
Sodium alginate is a naturally occurring biodegradable polysaccharide, 
extracted from brown seaweed. It is a copolymer of 1,4- linked ß -D- 
mannuronic acid (M) and a- L- guluronic acid (G) . Its ability to solidify relies 
on the G blocks being chelated by divalent calcium and forming structures 
proposed to resemble eggs in an egg box junction'. Using an alginate 
surface to grow biofilm on, before dissolving the bead, and liberating the 
previously adherent bacteria had not been tried before, but seemed like an 
elegant solution worth developing further. 
For the reasons outlined above, a submerged alginate substratum biofilm 
model with semi- continuous batch culture was selected. A single species 
staphylococcal biofilm was cultured in an enriched medium, exposed to in 
vivo levels of antibiotics up to concentration 2048mg /L for 3 hours. The 
bacteria were directly enumerated after dissolving the alginate substratum 
and liberating the biofilm. Outcome measures of the model were divided 
into technical and practical aspects. Practical aspects included cost 
effectiveness, in terms of materials equipment and technicians time, as well 
as the ability to guide clinicians' decisions in a real world time frame. A 
technically satisfactory method would have repeatable control data and 
reliably demonstrate what proportion of the bacteria was killed by an 
antimicrobial. 
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2. Materials and Methods 
72 
2.1. Materials 
2.1.1. Bacterial Strains 
Three staphylococcal strains were used; a reference strain and two clinical 
strains isolated from patients with PJI at the Royal Infirmary of Edinburgh. 
All were sub -cultured and stored in 10% glycerol at -70 °C. A Methicillin 
Sensitive Staphylococcus aureus MSSA -'F' was isolated from infected metal- 
work used to reconstruct an elbow fracture. A coagulase negative 
staphylococcus CNS -'J', isolated from an infected hip replacement. MSSA- 
'N' (American Type Culture Collection 29213) was a S. aureus reference strain 
which had been extensively studied in its biofilm state109,231,240and was used to 
facilitate comparison of the final protocol to other techniques. 
2.1.2. Media 
Luria broth (LB): Difco bacto tryptone (10 g), Difco bacto yeast extract (5 g) 
and NaC1 (10 g) were dissolved up to 1L of dH2O. The pH was adjusted to 
7.2 prior to autoclaving. Tryptic soy broth (TSB): Pancreatic digest of 
casein(17g), peptic digest of soybean (3g), glucose (2.5g), NaC1 (5g), 
dipotassium hydrogen phosphate (2.5g) was dissolved up to 1L with dH2O 
and the pH adjusted to 7.3 prior to autoclaving. Solid LB agar: Broth was 
solidified by adding 15 g/L difco agar prior to autoclaving. 
2.1.3. Common materials and solutions 
Disposables were used as follows: 0.2um sterilising filters, Minisart R 
Sartorius Biotech GnbH; Pipette tips, Greiner Bio -One Ltd. Gloucestershire 
GL103SX; Greiner 50m1 and 15ml CELLSTAR PP- Falconi tubes; Greiner 96- 
well round -bottomed micro -titre plates were used for forming the bead in 
and NUNC 96 well flat bottom microtitre plate 300u1 were used to perform 
the optical density measurements and micro- dilutions, Sigma -Aldrich 
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Company Ltd. Dorset SP8 4XT; IWAKI flat bottomed 48 well polystyrene 
plates with 1.76 ml capacity, were used for alginate bioassays; Bibby 
Scientific Limited, Staffordshire, ST15 OSA, UK. 
All chemicals were of reagent grade and obtained from standard suppliers. 
Solutions were autoclaved prior to use unless stated. A 4% (w /v) sodium 
alginate solution was prepared in warm water with agitation. 100m1 was 
enough to make around 200 beads. A 2M solution of calcium chloride 
containing 29.4g made up to 100m1 with sterile dH2O was enough to chelate 
around 400 beads. A universal neutralizer was used to counteract free 
radicals and minimise antibiotic carry over. It was made up to 20m1 in 
double distilled water and composed of 1.0 g L- histidine, 1.0 g L- cysteine and 
2.0 g reduced glutathione. The solution was filter sterilised with a 0.20µm 
filter and stored at -20 °C. A solution containing 0.05M Na2CO3 and 0.02M 
citric acid was used to dissolve alginate beads. 10x stock solution made by 
making up 5.3g of Na2CO3 and 3.8g of Citric acid to 1L in dH2O. 
2.1.4. Antibiotics 
The antibiotics used in this study (listed below) were purchased via NHS 
Lothian pharmacy. Liquids and reconstituted powders were used as stock 
solutions and stored as per manufacturers instructions' until being diluted 
immediately prior to use. 
Linezolid - Zyvox ® 2000mg /L Pharmacia, Sandwich, Kent, CT13 9NJ 
Gentamicin - Cidomycin ® 4000mg /L Sanofi Aventis, Guildford GU14YS 
Rifampicin - Rifadin ® 400mg /L Sanofi Aventis, Onslow Street Guildford 
Ciprofloxacin - 2000mg /L PLIVA Pharma Ltd, Petersfield, GU32 3QB 
Vancomycin - 4000mg / L Wockhardt UK Limited Wrexham LL13 9UF 
Clindamycin - Clindamycin -Cleocin ® 4000mg /L Sanofi Aventis, Guildford 
Daptomycin - Cubicin ® 4000mg /L Cubist Pharmaceuticals, Lexington,USA. 
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2.2. Methods 
2.2.1. Alginate bead topography 
Alginate beads were measured to calculate their surface area using vernier 
calipers measuring to nearest 0.1mm. The surface area was calculated by 
dividing the bead into 2 parts. 
i. Surface Area of a 1 ended Cylinder = n r2 + 2n *r *h, 
ii. Surface Area of half a Sphere = 2n r2 
Therefore, 1 -ended Cylinder is 114.51mm2 and half sphere is 45.80mm2, 
making a total surface area of 160.31 mm2 (Figure 2.1) and average weight of 



















Table 2.1: Bead topography 
Diameter 
Figure 2.1 Bead shape 
Height 
2.2.2. Generation time in rich media growth conditions 
To ensure the microtitre conditions were resulting in normal exponential 
planktonic growth, the generation time was calculated for MSSA -F (Figure 
2.2). Freezer stocks were cultured overnight in 5m1 of tryptic soy broth (TSB) 
and plated on to agar. A typical colony was then sub -cultured overnight in 
5m1 TSB. Stationary phase organisms were added to 200111 TSB to make a 
final concentration of 10 6/ ml in a 96 well plate and placed in an orbital 
incubator set at 200 rpm and 37° for 24 hours. Three wells were sampled at 1, 
2, 3, 4, 5, 6, 12, 13 and 24 hours, diluted and then plated on to LB agar using 
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the Miles Misra technique24' which is detailed below in section 2.2.4. The 
method of calculation of generation time242 assumes that as bacteria grow by 
binary fission, the increase in population is by geometric progression where 
G (generation time) = (time) / n (number of generations). As n is related to 
both B and b (number of bacteria at the beginning and end of time interval 
respectively) by the equation b = B x 2n it can be resolved to n = 3.3 log b /B 
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Figure 2.2: Generation time of planktonic MSSA -F in TSB. 
Fitted circles are the mean Log 10 CFU recovered with the bars representing the SD. 
t is the time interval, B is the number of bacteria at beginning and b is the number of bacteria 
at the end of the time interval. 
Therefore the generation time of the F strain in these conditions, was 
calculated as: 
G =t /n 
G = 299 - 187mins / 3.3 (7.84 - 6.86) = 112 / 3.27 
G = 34.3 minutes per binary division which is in keeping with the 
normal range for these conditions 242. 
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2.3. Standard Operating Protocol 
After the results of chapter 3 had been taken into account the final version of the 




C Staph aureus 
MSSA 
Figure 2.3: Overview of final standard operating protocol 
2.3.1. Preparation of alginate beads 
Sterile reagents were added, in the order listed, into each of the 96 U shaped 
wells using an 8- channel pipette in a horizontal laminar flow chamber: 10/.11 of 
2M CaCI; 2 x 104l 4% sodium alginate was back -pipette to avoid clogging the 
tips; a fine mist of 2M CaC12 was sprayed over plate using a sterilized pump; 
another 2411 of 2M CaC12 was added once a flat chelated surface had formed; the 
plate was covered with its lid, sealed with paratape and stored at 4 °C. 
2.3.2. Preparation of the organisms 
An overnight culture of freezer stock in 5m1 of LB was aerobically incubated at 
37 °C, streaked onto agar plates and incubated overnight at 37 °C; two 
morphologically consistent single colonies were sub -cultured overnight in 
duplicate 5ml LB bottles at 37 °C; a starting inoculum of 10 7 CFU / ml was made 
up by the measuring the optical density of the overnight stationary phase sub- 
culture @ 600nm before being confirmed by 10 fold serial dilutions and plating 
using Miles Misra method, as detailed below in section 2.2.4. 
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2.3.3. Growing and challenging the biofilms 
Reagents were added into each of the 48 flat -bottomed wells in order: 60001 
LB with a final concentration of 107 CFU /m1 stationary phase organisms was 
pipetted into wells A 1 -6, E 1 -6 and Cl (Figure 2.4); into which the alginate 
beads, after being rinsed in sterile water, were added; the plate was 
incubated at 37 °C in an orbital shaking incubator, (Gallenkamp Weiss 
Technik UK), set at 150 rpm for 20 hours. Using a flame sterilised wire, the 
beads were transferred to adjacent rinsing wells B1 -6 F1 -6 and D1 containing 
600p1 of sterile water for 1 minute. Two unchallenged growth controls B1 
and D1 recovered and enumerated (section 2.3.4). The remaining 11 beads 
were transferred to challenge wells C2 -6 and G1 -6 containing the 
antimicrobial(s) at desired concentration in 600 pl LB for 3 hours. The beads 
were rinsed for a second time in wells D2 -6 and H1 -6 with 60041 sterile water 
for 1 minute before being dissolved as detailed below. 
2.3.4. Recovering the organisms 
The dissolving solution contained 1ml of universal neutraliser made up to 
40mis with 0.02M citric acid & 0.05M Na2CO3. It was titrated to pH 6.8 and 
sterilised with 0.2.ím filter. Each bead was placed into a separate 15ml 
Falconi tube containing 1 ml of dissolving solution and crushed using a 
flame sterilised glass -stirring rod for 10 seconds. Another 1ml of dissolving 
solution was added and the tube was placed in rotating rack for 15mins. 
After the bead had dissolved, the tube was vortexed for 10 seconds before 
being 10 fold diluted six times using PBS in flat bottomed 96 well plate. Each 
bead was plated using the micro Miles Misra technique onto LB agar and 
incubated at 37 °C for a minimum of 48 hours before resulting no growth. 
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10bí1 of each dilution was sampled using a multichannel pipette and dropped 
onto a LB agar dish from 1cm (Figure 2.5). Five technical replicates were 
performed. After the drops had been fully absorbed into the agar (20 
minutes), the plate was turned upside down and incubated at 37°C. Plates 
were manually enumerated after 24 hours (48 hours if no growth was seen at 
24 hours). It became difficult to read the technical replicates when there were 
more than 20 CFU per drop and so 3 -15 CFU was found to be an optimal 
number to record as a result. If the CFU numbered less than three on the 
least dilute row and the colonies were both within the drop and 
morphologically consistent, with the organism being assayed, they were 
included in the results. 
The Log Density (LD) per biological replicate was calculated by logro 
transforming the product of the mean of the five technical replicates and the 
dilution factor of 200 (2 ml of dissolving solution x 100 to adjust for sample 
volume). The lowest possible value recordable using this technique was 
therefore 1 colony in the 5 replicates of the least dilute row, which equates to 
LD of 2.6. If there was no CFU visible, it was recorded below the minimum 
detectable limit and assigned at half that level at 2.3 LD, instead of zero. As 
all the samples were taken from the same well, the mean of all 5 technical 
replicates was recorded and the median of a minimum of 3 biological 
replicates for each condition was resulted along with the inter- quartile 
ranges. 
2.3.5. Data handling, graphical illustration and statistical analysis 
Data was analysed using GraphPad Prism 6 for Mac OS X (GraphPad 
Software, San Diego California USA, www.graphpad.com) software for 
statistical analysis and graphing. The author performed all standard 
analyses, the only exception being a fully nested ANOVA test that was done 
using SPSS Version 14 with advice from a senior medical statistician. 
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Figure 2.4: Schematic of 48 well plate used in alginate biofilm model. 
Two growth controls and 11 biological replicates per plate. Only one growth 
control shown for simplicity but there was normally a second control in well Cl 
(wells A -H are left to right). 
Figure 2.5: Example of Miles Misra enumeration method. 
Each agar plate is a different biological replicate. 5 technical replicates are plated 
from left to right in each plate with 6 dilutions top to bottom from 10 to 10 fold. 
Although median result is written on plate, the mean was used in results. Results 
from top left clockwise: LD of 5.6, 6.1, 5.9 and 6.4 once dilution and loglo 
transformation was performed for each biological replicate. 
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2.4. Microscopy 
2.4.1. Epifluorescent light microscopy 
A S. aureus strain that had been transformed with a plasmid vector 
containing the green fluorescent protein gene pHC60 was used to generate a 
biofilm on the bead using the SOP. After it was washed to remove non- 
adherent organisms it was sectioned with a sterile scalpel to approximately 
0.5mm thickness. This was viewed using a Zeiss light microscope with a 
Axiocam 1.4 megapixel camera and epifluorescent function (Carl Zeiss 
Microscopy Ltd Cambridge) 
2.4.2. Transmission Electron Microscopy 
Attempts to section the alginate bead were made using a microtome. 
Unfortunately both the unprepared bead and one that had been fixed in 2.5% 
glutaraldehyde solution were too soft to be sectioned to the thickest possible 
width of 100µm and could not be processed further. 
2.4.3. Electron cryo- microscopy 
A 20 -hour MSSA -N biofilm that had grown on the surface of an alginate 
bead was washed with water to remove non -adherent organisms. Under the 
guidance of Dr C Jeffree (University of Edinburgh's electron cryo- microscopy 
unit), the sample was rapidly frozen using a Gatan ALTO 2500 Cryotransfer 
module in it's native hydrated state to preserve the biofilm architecture. It 
was freeze -fractured to expose its internal microstructure and sputter- coated 
with gold -palladium to allow higher resolution surface imaging before being 
transferred under vacuum to the microscopy chamber. The FEI F20 electron 
microscope (200 kV, field emission gun) was equipped with an 8k x 8k 
CMOS camera. Images were processed using a dual Quad, 8 GB RAM 
computer that used the IMAGIC processing software (Image Science 
Software GmbH, Gillweg 3, Berlin, Germany) to convert images into tagged 
image file Format (tiff) format, typically 5MB in size. 
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Prosthetic Joint Infection (PTI) is a leading cause of morbidity in patients with 
orthopaedic implants. PJI are typically caused by adherent bacterial biofilms 
which are refractory to systemic antibiotics alone. It has been appreciated for 
over 20 years243, that the Minimum Inhibitory Concentration (MIC) of a 
planktonic culture is a poor predictor of PJI susceptibility. Despite this, the 
only method currently clinically available, to evaluate microbial sensitivity, 
is still based upon the MIC for a single antibiotic using either the ISO 20776 -1 
broth micro -dilution or a disc diffusion methodist The MIC is interpreted as 
a discriminating breakpoint concentration, thereby defining isolates as 
susceptible, intermediate or resistant227 to an individual antibiotic. 
The bacteria associated with PJI are in a sessile biofilm rather than the 
planktonic state they are tested in routinely. It has been established that, 
even in the absence of specific antibiotic resistance factors, sessile organisms 
in biofilms are generally between 100 -1000 times more tolerant to antibiotics 
than when they revert back into their planktonic state66'109 No current 
clinical method of in -vitro susceptibility testing considers the pathogens' 
sessile state or accurately reflects the higher antibiotic levels frequently 
delivered locally, and often in combinations, to treat prosthetic infection. 
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In the present study, a method described by Mater et al.23s to immobilise cells 
from a late growth phase Pseudomonas spp. within a bead of 2% (w / v) 
sodium alginate, by chelating the alginate using calcium chloride 0.07M, has 
been adapted. These authors demonstrated that if the beads were dissolved 
with a sodium carbonate and citric acid solution then 100% of the organisms 
remained viable and could be quantified as colony forming units (CFU) by 
plating. An attractive feature of this approach was that after the bead was 
dissolved, the biofilm would have no surface to remain attached to and so 
recovery would be maximized, compared to other methods such as 
sonication which is commonly used to liberate bacteria from solid 
surfaces224,244,245 
3.1.1. Aims 
The aim of this chapter was to develop a biofilm model which met the 
following requirements: 
i. Allowed the testing of sessile bacteria in biofilm with multiple 
antibiotics at high doses achievable with local delivery. 
ii. Had the ability to guide clinical decisions in a real world time frame 
more confidently than breakpoint discriminations of the MIC. 
iii. Was cost effective in terms of materials, equipment and technicians' 
time. 
iv. Produced repeatable control data. 
v. Demonstrated what proportions of the bacteria are killed by a 
antimicrobial. 




In order to establish and assess the value of a suitable biofilm model, it was 
firstly necessary to establish the growth profiles for the isolates under study 
in both planktonic and sessile conditions. Two clinical isolates of 
staphylococci were therefore examined: A Methicillin Sensitive S. aureus 
MSSA -F, and a Coagulase Negative Staphylococcus CNS -J, were isolated 
from patients with prosthetic infection at the Royal Infirmary of Edinburgh. 
3.2.1. Optimising planktonic growth 
Three different culture media were initially compared to optimise planktonic 
growth conditions. Tryptic Soy Broth (TSB) is a commonly used medium in 
staphylococcal biofilm research230,246 It was compared to Luria -Bertani broth 
(LB247) which was used routinely by the laboratory in which the 
investigations were carried out, and also to LB with the further addition of 
7.5% (w /v) NaC1 (SLB). This additional osmotic stress has previously been 
shown to enhance biofilm formation in MSSA isolates by up- regulating the 
ica locus that controls PIA secretion'. 
To establish the growth profiles, 96 well plates containing 20041 of fresh 
medium was inoculated with 10' CFU / ml of either MSSA -F or CNS -J, 
previously grown overnight in 5m1 LB at 37 °C. A microplate absorbance 
spectrophotometer with a built -in incubator and plate shaker set to 37 °C and 
at 200rpm (BioRad Laboratories Ltd.) was used for incubation whilst the 
optical density at 600nm, was measured every 30 minutes. There were 14 
biological replicates in each of the six possible organism / medium 
combinations and sampling continued until stationary phase was well 
established (Figure 3.1). In order to calculate the bacterial generation time 
under these conditions ( Figure 2.2 in section 2.2.1), sampling of additional 
wells containing MSSA -F in TSB was undertaken every hour. Samples of 
these three biological replicates were micro- diluted and then plated on to LB 
agar using the Miles -Misra technique'. 
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Examining figure 3.1, it can be seen that LB with added NaC1 (SLB) has the 
poorest exponential growth rate and lowest peak OD. TSB allowed both 
organisms to stay in their exponential growth phase for longer. However 
their generation time in the exponential phase seemed similar. The apparent 
biphasic growth seen for MSSA -F in SLB is likely to reflect an artifact optical 
density measurement (discussed in section 3.4.1) as the standard deviation 
seen was much higher in this group and no other plausible explanation was 
found. Because CNS -J also grew poorly in SLB the experiment was not 
repeated. 
3.2.2. Optimising sessile growth 
The hypothesis that the medium producing the highest bacterial numbers in 
the planktonic state should also produce the highest sessile numbers on the 
bead surface was then tested. 
The LB, SLB and TSB media were inoculated to a concentration of 10' 
CFU / ml with either CNS -J or MSSA -F. 10mis of each combination was then 
added to individual 25ml conical flasks, each containing 4 alginate beads, 
and incubated aerobically in an orbital shaker set at 50 rpm and 37 °C, for 20 
hours. Subsequently, the beads were removed and gently rinsed twice with 
PBS solution to dislodge non -adherent organisms. The beads were then 
dissolved into 3m1 of sodium carbonate / citric acid solution (see section 
2.2.4) before micro -dilution and enumeration of the liberated bacteria, using 
the Miles Misra technique, described in the methods', onto LB agar. A 
minimum of three biological replicates in each group was done and as the 
variance in each group was found to be unequal, the results were compared 
using the Kruskal- Wallis test and post tested using Dunn s multiple 
comparisons test (Figure 3.2). 
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The results shown in figure 3.2 do seem to show similarity in trend to those 
obtained for the planktonic culture in figure 3.1, with the TSB having the 
greatest mean Log10 Density (LD) of sessile organisms recovered. However 
the differences in the means were only statistically significant between the 
SLB and LB for MSSA -F and between LB and TSB for the CNS -J. The beads 
in the TSB group had a noticeably softer consistency as they were being 
transferred between containers. Although advantageous as the alginate 
dissolved in the solvent more easily, questions remained however as to 
whether the beads would remain robust enough to allow incubation for a 
longer time. 
3.2.3. Sessile growth over time 
To examine how the organisms grew when forming a biofilm over time, five 
parallel cultures with four alginate beads in each 25ml conical flask 
containing 10mis of either LB or TSB were prepared. They were inoculated 
to 10' CFU / ml with CNS -J and incubated aerobically in an orbital shaker at 
37 °C, 50 rpm. At 3, 20, 45, 77 and 96 hours four beads were washed, 
dissolved and enumerated as detailed above. 
The beads incubated in TSB were found to be too fragile after 45 hours to 
handle and so were not examined further. Figure 3.3 demonstrates that the 
adherent organisms divided steadily for the first 45 hours in this closed 
system, at which point the number of viable organisms recovered declined 
slowly. Focus moved away from further replicates of this experiment onto 
modifying the protocol in an effort to improve the robustness of the bead. 
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Figure 3.1: Planktonic growth curves comparing 3 different media. 
Mean Optical Density at 600nm with SD (bars) is shown for 2 strains and 3 different 
mediums. 
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Figure 3.2: Comparison of sessile growth in 3 different media LB, SLB and 
TSB with both MSSA -F and CNS -J organisms. 
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Figure 3.3: Growth curve of MSSA -F biofilm on alginate bead in LB over time 
Each closed circle is the mean of the 5 technical replicates and expressed as Logo 
CFU. 
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3.2.4. Modifications to the bead 
In order to investigate whether the bead could be made more robust whilst 
in media, the concentration of sodium alginate was increased from the 
original method. 2 %, 3% and 4% alginate were made in triplicate. Their 
mean wet weight was recorded before and after they were submerged in 
sterile LB for 6 days in static aerobic conditions at 37 °C. Although all the 
beads were observed to physically swell after immersion, table 3.1 confirmed 
that the 4% alginate bead had lost the least mass. As it was felt that any loss 
was most likely to have arisen from the interface between the bead and the 
liquid, the 4% bead was chosen for the SOP. 
In an effort to increase the surface area of the bead, its volume was increased 
from 100 to 2000. As a consequence, they were only peripherally chelated 
and a more concentrated 2M calcium chloride solution was needed to 
consolidate their centre. The order and volume in which the reagents were 
added was also crucial to prevent a central lagoon of calcium chloride from 
forming and to ensure the top surface was flat (section 2.2.1). 
3.2.5. Initial inoculation 
In order to facilitate comparison with the MBECTM device224, many of it's 
incubation conditions were adopted. However, in an attempt to maximise 
the number of organisms recovered, the initial inoculation concentration of 
CNS -J was increased from 10' CFU / ml to 108CFU / ml. The flasks were 
placed in a 37 °C static incubator for 20 hours. The beads were then rinsed 
twice with PBS solution and each bead was dissolved into 3m1, before 
dilution and plating as described previously. From the data presented in 
Table 3.2 however, it can be seen that no advantage was gained from using 
the higher starting inoculums and 10' CFU /ml was used in subsequent 
experiments. 
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3.2.6. Shear Stress during incubation 
Shear stress has previously been shown to impact on the quality of biofilm 
formation'. In order to relate well to the natural situation for biofilm 
formation, it was important that the shear stresses applied to the beads was 
sufficient to result in firm biofilms but without disrupting their integrity. 
To address this point, four beads were added into each 25ml conical flask 
filled with LB as before. The flasks were inoculated with 10mis of LB 
containing 10' CPU/ ml of CNS -J and incubated at 37 °C for 20 hours at 0, 50, 
150 or 200 rpm in an orbital shaker. The data in Table 3.2 shows that 150 rpm 
was the optimal setting which maximised biofilm growth without the 
mechanical failure of the beads that was seen at 200 rpm (figure 3.4). 
3.2.7. Rinsing solution 
PBS was initially used to rinse away any non -adherent organisms because of 
its physiological pH and osmolarity. It was noted however to be associated 
with degradation of bead structure and was substituted with sterile water. 
3.2.8. Incubation vessel 
The final modification to the SOP was to switch from using 25 ml conical 
flasks containing five beads in 10mis of media to a single 48 well flat - 
bottomed polystyrene plate. The beads were transferred between adjacent 
wells, each containing 6O041 of medium (figure 3.5). This was mainly done 
for logistical reasons as it greatly reduced preparation time, amount of 
reagents that were needed, and allowed more biological replicates to be done 
per week. As a further advantage, it minimised the bacterial aerosol 
biohazard and risk of cross -contamination whilst maintaining the reliability 




Initial weight of 3 Weight of 3 beads at 6 % Weight 
bead (pg) days (1g) lost 
2 634 523 17.5 
3 621 562 9.5 
4 681 644 5.5 
Table 3.1: Sodium alginate concentration influences the wet weight of beads 
after 6 days in static sterile LB broth at 37 °C 
Characteristic Condition Handling Dissolving LD 
Starting 
inoculation 
(2 tailed test p = 
0.27) 
Static test low 
inocula 
10' CFU / m1-1 
+ + 
4.57 ± 0.31 
n =4 
Static test high 
inocula 
108 CFU / m1 -1 
4.37 ±0.05 
n =4 
Shear stress within 
orbital incubator 
Static ++ - 
6.31±0.67 
n=4 
50 rpm ++ - 
6.19 ±0.57 
n =16 
150 rpm + ++ 
6.97 ±0.47 
n =41 






Water + ++ NR 
Incubation vessel 
25ml conical flask 





48 well plate CNS -J 





Table 3.2: Summary of bead characteristics dependent on incubation 
conditions. 
LD - Mean Log10 Density = Log10 CFU, +/- Standard Deviation, ++ Favourable, + 
Workable, - Unfavourable, NR - Not Recorded, n - number of replicates 
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Figure 3.4: Appearance of beads after agitation at 200 rpm for 20 hours 
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Figure 3.5: Schematic of 48 well plate used in alginate biofilm model. 
Two growth controls and 11 biological replicates per plate. Only one growth 
control shown for simplicity but there was normally a second control in well Cl 
(wells A -H are from left to right). 
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3.2.9. Assessment of the alginate biofilm model 
The method is fully detailed in section 2.3 but briefly a 4% (w /v) sodium 
alginate solution was chelated with 2M calcium chloride using a round 
bottom, 96 well plate to mould bullet shaped beads with a surface area of 
161mm2- Each bead were then removed and incubated in 60041 of LB, 
inoculated with 107 CFU / ml -1 of either MSSA -N or CNS -J for 20 hours in a 
single well of a 48 well micro -titre plate. The beads were washed 
individually with water to remove non -adherent bacteria, growth controls 
were sampled before the remaining beads were placed in fresh LB (60001) 
containing antibiotics. After 3 hours of antibiotic challenge, the beads were 
removed, washed with water and dissolved in a solution containing 2mls of 
0.02M citric acid and 0.05M Na2CO3 , supplemented with a universal 
neutralizer249 detailed in section 2.1.4. Viable organisms were enumerated 
after micro -dilution and Miles Misra plating onto LB agar. 
3.2.10. Method of SOP assessment 
The author elected to use an established system for analysing biofilm data25o 
in order to facilitate comparison to reports by other authors more easily. The 
3 central tenets of the approach was to assess: 
i. Resemblance - Determining how repeatable the control data was. 
ii. Responsiveness - Determining how effectively the antimicrobial killed 
the organism. 
iii. Repeatability - Determining how repeatable the disinfections were. 
The data was analysed in 4 steps 
i. Login transform CFU /bead into LD before calculating their 
descriptive statistics 
ii. Perform a fully nested ANOVA of all controls to calculate 
resemblance. Satisfactory if SD < 0.6 
251. This also describes the 
proportion of error that is attributable to either intra- or inter- 
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experimental factors. 
iii. Perform a one -sample Students t -test against a hypothesised mean of 
0 to calculate responsiveness. Satisfactory if p < 0.05 
iv. Use the SD of LR in a one -sample t -test to assess repeatability. 
Satisfactory if SD < 0.7 252 
3.2.11. Resemblance of control data 
Unchallenged beads that had been inoculated for 20 hours were dissolved 
and the organisms recovered as detailed above. Data from all 38 
experiments that used the CNS -J and 43 experiments that used the MSSA -N 
reference strain were included. The ANOVA was nested, so that each 
biological replicate is found in combination with only one value of the 
higher -level nominal experiment. 
Figure 3.6 shows the distribution of 67 CNS -J controls measured over 38 
experiments. The mean LD was 6.08 with a SD of nested ANOVA of 0.34. 
72% of the variance was attributed to be intra- experimental and 28% of 
variance inter- experimental. 
Figure 3.7 shows all 78 controls from the 41. experiments using MSSA -N. The 
2 outliers (circled data points) were more than 3 SD from the mean LD of 
6.98. If they were excluded, the SD fell from 0.53 to 0.35. 49% of the variance 
was attributed to be intra- experimental and 51% of variance inter - 
experimental. This level of error falls within guidelines that indicate an 
acceptable resemblance251 and confirms that the growth control data for both 
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Figure 3.6: Resemblance of CNS -J growth controls 
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Figure 3.7: Resemblance of MSSA -N growth controls 
78 growth controls from 41 experiments using the SOP to test MSSA -N 
2 outliers more than 3 SD from mean are circled 
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3.2.12. Responsiveness and repeatability of antibiosis 
Figure 3.8 and table 3.3 demonstrate that at all the concentrations tested 
(apart for 16mg / L), the beads were significantly disinfected when they were 
exposed to gentamicin for 3 hours using the growth controls as a 
comparison. The t -test in table 3.3 depended on the assumption that the data 
are normally distributed, which could not be assured in the 3 replicates 
performed for 32, 16 and 8 mg \ L. Thus, a reasonable conclusion would be 
that the effects are quite definite at high concentrations but interpreted with 
care at low concentrations. 
The SD of each gentamicin concentration represents how repeatable the 
antibiosis was between biological replicates. Guidelines suggested a 
satisfactory SD would be < 0.7 252. All concentrations except 256 and 128mg/1 
produced repeatable logro reductions using this definition (table 3.3). These 
concentrations are important however, as they were around the levels that 
produced a logro reduction of 3 that defined a study end -point, MBEC. 
3.2.13. Sterility of technique 
Sterility was tested by inoculating six alginate beads in wells Al, 3, 5 and E 1, 
3, 5, placing them between sterile control beads in LB (Figure 3.5). The beads 
were alternately washed, dissolved and plated in the same manner as 
adjacent inoculated beads (Figure 3.9). One of the six agar plates had a small 
but clinically significant recovery of organisms (LD 3.08) probably 
representing cross -contamination from an adjacent bead or well. One plate 
also had an aerosol contaminant with obviously different colony morphology 
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Figure 3.8: Responsiveness and repeatability of disinfection. 
MSSA -N exposed to gentamicin for 3 hours. 
Gentamicin 
concentration mg \ L 
t-test 
treated vs. control 
SD 
2048 p<0.001 0.31 
1024 p<0.001 0.24 
512 p<0.001 0.39 
256 p<0.001 0.78 
128 p<0.001 1.41 
64 p=0.002 0.61 
32 p=0.039 0.65 
16 p=0.094 0.26 
8 p=0.010 0.12 
Table 3.3: One sample t test between disinfected and control samples. 
MSSA -N exposed to gentamicin for 3 hours. 
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3.3. Microscopy of Biofilms 
3.3.1. Epifluorescent light microscopy 
Several attempts were made to visualise biofilms to confirm they displayed a 
typical appearance and were limited to the surfaces of the bead. Initially a S. 
aureus strain that had been transformed with a plasmid vector containing the 
green fluorescent protein gene (see 2.3.1) was cultured on a bead using the 
SOP. After washing the bead to remove non -adherent organisms, it was 
cross -sectioned with a sterile scalpel to approximately 0.5mm thickness. 
Slices were viewed using a light microscope with an epifluorescent function 
(Figure 3.10). 
3.3.2. Cryo- scanning electron microscopy images 
Attempts at both confocal and transmission electron microscopy were 
unsuccessful (data not shown) as the alginate could not be adequately fixed 
to enable thin enough sections to permit light transmission through the 
samples. This led to attempts to try scanning electron microscopy (SEM); this 
was avoided initially as it involves vacuum desiccation and can disrupt the 
micro- architecture of the biofilm253. A cryo -SEM technique was chosen 
which minimised such artefacts and also allowed the beads to be fractured 
without contaminating the interior surface (Figures 3.11 -3.14) 
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Figure 3.9: Experiment to test sterility of SOP. 
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Figure 3.11: A cryo -SEM image taken perpendicular to the bead showing the 
alginate in the background with the Extracellular Polymeric Substance (EPS), 
secreted by and encasing the colonies of S. aureus. 
Alginate bead 
: A/ 13.1 mm x600 SEW) 08/03/10 13-32 
1 1 1 1 1 11 11 1, 
. 
5OOurn 
Figure 3.12: A cross section produced by fracturing a frozen bead. A thin layer of an 
ice artefact can be seen on the top surface, with what perhaps is colony of S. aureus 
standing proud. The FPS appears to be 15 -20 um thick and no organisms are seen 
below this depth within the alginate. 
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Figure 3.13: A cryo -SEM image taken perpendicular to an area of the bead 
where the extracellular polymeric substance (EPS), secreted by and encasing 
the colonies of S. aureus are sparse. The alginate bead substratum is clearly 
seen in the background. 
Figure 3.14: An 3 dimensional anaglyph using red and cyan encoding of a 
cryo -SEM stereogram taken perpendicular to the bead showing the alginate 
in the background with the extracellular polymeric substance (EPS), secreted 




3.4.1. Planktonic growth cultures 
Typical growth curves were observed for the clinical strains CNS -J and 
MSSA -F with the latter being shown to have a generation time of 34 minutes 
(Figure 3.1). As the generation time falls within the normal 30 -52 minute 
range seen in the Staphylococcus aureus254 this suggests that the strain is not a 
stable small colony variant (SCV), which typically replicate much slower due 
to a defective electron transfer chain255. 
After a 90 minutes lag phase, both organisms entered a more prolonged 
exponential phase in TSB than the other media (Fig 3.1). This is explained by 
its higher glucose concentration, a preferred carbon source for S. aureus, 
allowing glycolysis to continue for longer256'257 and resulting in a higher final 
OD. The exponential phase is known to tail off when either the 
concentration of glucose falls or acetic acid, the by- product of aerobic 
glycolysis, rises. Therefore, any post exponential growth involves activation 
of the Tricarboxylic Acid (TCA) cycle258'259, which facilitates catabolism of 
non -preferred carbon sources and enables oxidative phosphorolation using 
the Electron Transfer Chain (ETC). 
At the point that one would have expected the rate of cell death to increase, 
the OD did not decline in most of the groups (Figure 3.1). However there 
were 2 groups (CNS -J in LB and MSSA -F in SLB) that demonstrated 
unexpectedly rapid declines in their OD with time. This reduction in 
turbidity cannot easily be explained biologically and the most likely 
explanations are bacterial clumping or misalignment of the internal 
geometry of the spectrophotometer (Fig 3.15) causing false optical density 
measurements as light is scattered by the sample. The aberrant data were 
not critical to the aims of these experiments and so were not repeated. 
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Figure 3.15: Internal geometry of spectrophotmeter. 
Misalignment may cause aberrant optical density measurement as light is 
scattered by the sample. Reproduced from'. 
3.4.2. Sessile growth curves 
The addition of more NaC1 into the LB (SLB) was investigated, as previous 
studies261,262 found both MSSA and CNS isolates were more likely to form 
biofilms in media supplemented with NaCl. This was reported to be 
achieved primarily by icaADBC operon dependent up- regulation of PIA after 
the additional osmotic stress (see section 1.3.2). In the current study 
however, SLB was not found to result in an increase in the number of CFU 
recovered from either the planktonic or sessile cultures (Figures 3.1 and 3.2) 
as well as having a detrimental effect upon the robustness of the beads. 
Figure 3.3 demonstrated that sessile LD was maximal at 48 hrs. As the 
experiment used a closed system and planktonic growth was also occurring 
in the broth, this post- exponential growth is likely to have been TCA 
dependent. This view is supported by comparing the data in figures 3.1 and 
3.2 that show that the differences between media are less pronounced with 
sessile compared to planktonic growth. The planktonic organisms are 
expected to use the glycolytic pathway favored by the TSB whilst the sessile 
organisms are able to catabolise the non -preferred carbon sources that are 
plentiful in all three media, using their TCA cycle. 
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3.4.3. Modification to the Standard Operating Protocol 
The many alterations in the methods slowly improved both the bead 
robustness and recovery of more sessile organisms. Utilising the 48 well 
micro -titre plate as the incubation vessel provided the greatest single 
improvement. This reduced reagent cost, increased productivity and 
exposed the investigator to less biohazard when handing the samples. 
Both PBS and TSB seemed to be detrimental to the bead's integrity. Sodium 
alginate is a naturally occurring polysaccharide extracted from seaweed and 
is a copolymer of a- L- guluronic acid (G) and 1,4- linked ß -D -man uronic acid 
(M). Divalent calcium ions are proposed to form 'egg box junctions' between 
the homopolymeric GG blocks, with the alginate chelating the calcium into 
an alginate gel. 
TSB contains dipotassium phosphate and the competing charged function of 
the phosphate ions, also present in PBS, appeared to strip the bead of its 
calcium and mechanical integrity. This effect has been seen to increase with 
temperature and pH > 5.5263,264 Further work aiming to extend the bead's 
endurance in a variety of growth conditions may be achieved by replacing 
the chelator calcium, with another biocompatible divalent cation which has a 
higher affinity for alginate, such as strontium or barium'. 
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3.4.4. Assessment of the Alginate Biofilm Model 
The SOP was found to have satisfactory resemblance of controls (Figure 3.6 
and 
3.7)251,266,267 and responsiveness at higher gentamicin levels but 
repeatability of antibiosis252 was less satisfactory around the critical levels 
used to define the MBEC (Figure 3.8 and table 3.3). This trend of has also 
been seen by other authors who used a submerged substratum 
method224,229,246. This widening of the SD around the MBEC has also been 
observed in studies that have used a time kill method230,268,269 rather than the 3 
hour time interval employed in this study, which may bias toward antibiotics 
that kill in a more concentration -dependent manner. 
3.4.5. Sterility 
The SOP was tested in a rigorous fashion and even though there was 
evidence of cross -contamination in one of the six replicates (Figure 3.9), it 
would not have altered the statistical interpretation of the result, as it fell 
well below the level sufficient to alter the interpretation of the MBEC end- 
point. 
3.4.6. Microscopy of Biofilm 
Despite having some surface ice artefact, the cryyo- scanning electron 
microscopy technique, appeared to preserve the EPS and biofilm structure 
very well. The ability to fracture the frozen samples was useful and 
demonstrated that the biofilm appeared to be exclusively localised to the 
beads surface, thus preventing heterogeneous exposures to nutrients and 
antimicrobials. The findings were consistent with previous models that 
found 10% of the silastic substratum was colonised with S. aureus biofilm 5 -6 
cells thick within 2 hours of exposure27'. 
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3.4.7. Conclusion 
Returning to the original aims of the chapter, this alginate model allowed 
testing of staphylococcal biofilms exposed to single or multiple antibiotics at 
high doses achievable with local delivery. It resulted in repeatable control 
data and reliably demonstrated what proportions of the organisms were 
killed, in terms of reduced colony forming ability. Some concern remains 
about the repeatability of the response to the level of antibiotics that reduce 
the log density by around 3 (i.e. eradicate 99.9 %). However, no other biofilm 
assay has shown to have more repeatable data in this zone. Tests of 
robustness (ability to be accurate despite sub -optimal technique) and inter - 
laboratory repeatability have not been tested yet. 
Although the alginate biofilm model is inexpensive in terms of materials, it 
only lends itself to a moderate throughput (with 33 samples possible per 
day). Although this could be increased to perhaps 55 if the technician had 
access to pre -sterilised consumables and media, it still falls well below the 
level that would make it cost effective overall in a clinical setting. If further 
modifications to the alginate gel make it more mechanically stable then 
perhaps it could be used as a dissolvable coating to cover the 96 -pin micro - 
titre lid. Such an approach would benefit from high throughput and 
enhanced recovery of viable organisms. This is certainly worth pursuing, as 
the only similar validated technique, the MBEC test224, is expensive, 
complicated, and lacks robustness . 
This method did go some way to bridging the gap between in -vitro and in- 
vivo conditions which merits further development. 
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4. Combining antibiotics to treat 
prosthetic related infection 
4.1. Introduction 
In 1970 Buchholz and Engelbrecht167 first described using bone cement as a 
means to deliver high levels of antibiotic locally around orthopaedic 
implants. There is high quality evidence to show that antibiotic loaded bone 
cement does significantly reduce the clinical infection rate after primary hip 
and knee replacement 28,52,271. In cases where Prosthetic Joint Infection (PTI) 
has developed and local antibiotics have been used as part of the treatment, 
expert opinion and single centre series have demonstrated between 75 -91% 
clinical success with many diverse protocols 
Meta -analyses of these trials have concluded that the patient populations and 
treatment algorithms were too heterogeneous to draw any clinically useful 
inferences about the antibiotic ideal regime from the available data136'166 In 
lieu good quality clinical evidence, inferences about the optimal antibiotic 
dose or combination for therapy must be made with in -vitro experiments 
and with animal models before a properly controlled trial, comparing the 
most promising ones is commissioned. 
4.1.1. Current surgical practice 
Surgeons attempt to identify the infecting organisms prior to reoperation and 
optimise, on the basis the antibiogram, the number and class of antibiotics 
chosen for treatment m. Commercially available Antibiotic- Loaded Acrylic 
bone Cements (ALAC's) that contain gentamicin, with either clindamycin 
(Refobacin Revision® or Copal ®G+C) or vancomycin (Vancogenx'"-74), are 
commonly used. Surgeons occasionally hand mix a third antibiotic, if it has 
shown to be sufficiently heat stable and to elute well after the exothermic 
polymerization of the cement (examples include línezolid° , daptomycínn'ó 
and ciprofloxacin'93). As well as the local antibiotics and surgical 
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debridement, intravenous antibiotics are commonly administered for 
between 1 and 6 weeks post -operatively and converted to oral equivalents on 
discharge, although there appears to be no evidence to suggest there is a 
relationship between the length of the post- operative course and the final 
outcome27'278. There is also a paucity of evidence on whether local delivery 
of a single agent or a combination is superior. Saginur 279 used the Calgary 
biofilm device to test a number of Staphylococcal spp. and found their biofilms 
were not significantly affected by combinations of up to 3 of the following; 
linezolid, rifampin, cefazolin, oxacillin, vancomycin, gentamicin, 
azithromycin, ciprofloxacin or fusidic acid, in concentration ranges up to 
128mg /L. A recent review examining the choice and dose of antibiotics in 
ALACs came to the conclusion that "current recommendations are based on 
expert opinions and in -vitro studies, rather than on the results of randomized 
controlled clinical trials" 166 
4.1.2. Rationale for antibiotic choice and concentrations tested 
The antibiotics examined in this study reflect the most common and effective 
in current clinical practice28,161,202,280 The concentration at which they are 
eluted from the cement varies significantly and depends on a number of 
factors. These include: cement porosity281; how hydrophilic the PMMA 
structure is; the volume of fluid the antibiotics are eluted into176,178; the 
surface area of the cement; the assay used to measure elution; the physical 
state and chemical structure of the antibiotic's. 
In the current study, insufficient resources were available to perform an 
exhaustive checkerboard method that varied the antibiotic concentrations 
within each combination so the concentrations studied had to be rationalized 
after review of relevant in -vitro and in -vivo studies. In -vitro studies 
invariably found peak antibiotic concentrations on day one, with more than 
2/3 of gentamicin being released in the first hour174 (Figure 4.1). 
Concentrations of antibiotics eluted locally were reported as being between 
75 -426mg /L for gentamicin176,179,276,282, ciprofloxacin 54 -75mg / L193'202, 
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cli.ndamycin 407mg,1L202, linezolid 36- 64mg /L1 ,vancomycin 140 -200 
mg I Hendriks et al. demonstrated however, the possibility of much 
higher levels of gentamicin; up to 4000 mg /L if was sampled from the 1001,tm 
gaps found in the interfaces between the cement and the bone. Such 
interfacial gaps were seen around 10-15% of the cement mantle 
circumference with micro -CT 177. 
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Rifampacin dramatically alters the mechanical properties of bone cement193 
and is very bio- available orally. Therefore it is typically only used as 
systemic chemotherapy, rather than being delivered locally, which results in 
levels of around 4mg / L286. Although daptomycin can be successfully eluted 
from bone cement276 clinicians have been cautious to incorporate it as even 
low concentrations can result in myopathy287 and only a single case has been 
published to reassure surgeons about its side effect profile203 after local 
delivery have been published to date. If used systemically, daptomycin has 
been shown to have a peak serum level of 33mg / L288 and a peak bone level of 
4.7 mg / L289 in a rabbit model. Therefore both rifampacin and daptomycin 
were tested around their typical serum concentrations. 
When selecting combinations, antibiotics that were active against the same 
general bacterial targets were avoided. After rationalisation, a default 
concentration of 128 mg /L was chosen for the other five antibiotics 
commonly used in ALAC's to reflect the midrange between the high initial 
interfacial gap levels and the human in -vivo levels recorded from sites more 
distant from the cement such as seroma. 
4.1.3. Aims 
A series of experiments using the alginate model were designed to 
investigate: 
i. Whether high levels of antibiotics, delivered locally and in 
combination, were effective against the CNS -J and MSSA -N biofilms. 
ii. If there is a relationship between the minimum inhibitory, 
bactericidal, and biofilm eradication concentrations. 
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4.2. Results 
4.2.1. The Minimum Biofilm Eradication Concentrations (MBEC) 
To investigate whether a single antibiotic, delivered at a clinically relevant 
dose, would be effective at eradicating staphylococcal biofilm, a series of 
experiments were performed using seven antibiotics; gentamicin, 
vancomycin, daptomycin, clindamycin, ciprofloxacin, rifampacin and 
linezolid. Their effects were examined at concentrations between 4 and 
2048mg / L with a minimum of 3 biological replicates. Daptomycin was 
supplemented with Cali at a physiological level of 50mg /L as previous 
studies have shown this to result in an induced conformational change 
resulting in a more amphiphilic and bactericidal compound'''. 
The SOP is described fully in the Methods (section 2.3) but in summary, 
bullet shaped sodium alginate beads were inoculated in 600 µl of LB 
containing 10' CFU /ml of either MSSA -N or CNS -J (section 2.1.1) and 
individually aerobically incubated for 20 hours in a 48 -well micro -titre plate. 
Growth controls that were not exposed to antibiotic were sampled and 
enumerated. The remaining beads were gently washed with water to 
remove non -adherent bacteria and placed into 6O0111 fresh LB containing 
antibiotics. After 3 hours of antibiotic challenge, the beads were removed, 
washed with water and dissolved in a solution containing 2mls of 0.02M 
citric acid and 0.05M Na2CO3, supplemented with a universal neutraliser 
(section 2.1.3)249 Viable organisms were enumerated after micro -dilution 
and Miles Misra plating onto LB agar. CFU were logro converted into Log 
Density (LD) per bead. The minimum concentration needed to reduce the 
viable cell count by 3 LD's, compared to untreated controls, was defined as 
the MBEC (Figures 4.2 and 4.3). Since gentamicin is the most commonly 
utilised local antibiotic in clinical practice28, the other antibiotics MBECs' 
were compared against it using the Mann- Whitney U -test (Table 4.1). 
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Figure 4.2: Median log density (fitted circles) & inter -quartile ranges (bars) of 
CNS -J after exposure to single antibiotics. MBEC represents a log reduction 
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Figure 4.3: Median log density (fitted circles) & inter -quartile ranges (bars) of 
MSSA -N after exposure to single antibiotics. MBEC represents a log 
reduction of 3 from growth controls. 
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Both figures 4.2 and 4.3 demonstrated the same trend with only gentamicin 
and daptomycin observed to be effective bactericidal agents. Rifampacin, 
clindamycin, linezolid, vancomycin and ciprofloxacin did not reduce cell 
viability substantially over the 3 -hour exposure despite being orders of 
magnitude above the expected minimal bacteriocidal concentration'. Table 
4.1 confirms that the MBEC for gentamicin was statistically lower than the 
other antibiotics except daptomycin. The latter antibiotic exhibited a lower 
MBEC against MSSA -N but a comparable MBEC against CNS -J. 
Antibiotic MSSA-N CNS- J 
Vancomycin 0.004 0.006 
Ciprofloxacin 0.010 0.013 
Clindamycin 0.004 0.006 
Rifampacin 0.001 0.013 
Linezolid 0.010 0.013 
Daptomycin 0.004 0.34 
Table 4.1: p- values from Mann -Whitney tests comparing MBEC of 
gentamicin in experiments shown in Figures 4.3 and 4.4 with the MBEC of 
the other antibiotics. (p < 0.05 considered significant and in bold). 
4.2.2. Effects of combining antibiotics at concentrations 
achievable by local administration 
As previously discussed (in section 1.8), surgeons commonly combine 2 or 3 
antibiotics together and deliver them locally at the time of surgery. To 
investigate whether which combinations were efficacious in treating 
staphylococcal biofilm, a series of experiments were performed. The SOP 
was used to test the five antibiotics suitable for local delivery in 
combinations of two or three antibiotics. The final concentration of each 
antibiotic was 128mg /L in each well. Three biological replicates were 
performed for each combination and the recovered CFU / ml were converted 
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Figure 4.4: Median & inter -quartile ranges (bars) of CNS -J recovery after 3- 
hour exposure to a combination of 2 or 3 antibiotics at 128mg / L 
concentrations. 
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Figure 4.5: Median & inter -quartile ranges (bars) of MSSA -N recovery after 3- 
hour exposure to a combination of 2 or 3 antibiotics at 128mg /L 
concentrations. 
(G- Gentamicin, V- Vancomycin, CL- Clindamycin, CP- Ciprofloxacin, LIN -Linezolid) 
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As can be seen from the data shown in Figs 4.4 & 4.5, combinations of 
gentamicin and either ciprofloxacin or vancomycin, each at 128 mg / L, 
eradicated the biofilins of both isolates but combining ciprofloxacin and 
vancomycin together did not. Interestingly, despite both strains being 
sensitive to 128mg/L of gentamicin when tested alone (Figures 4.2 and 43), 
the combination of clindamycin or linezolid with gentamicin appeared to 
reduce its bactericidal effect markedly. 
4.2.3. Effects of combini g antibiotics at concentrations 
achie h both local and systemic administration. 
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Figure 4.6: Median & inter -quartile range of CNS -J recovery after 3 -hour exposure 
to a combination of 2 or 3 antibiotics at 128, 16 or 4mg /L concentrations. (G128 - 
128mg /L Gentamicin, R4 - 4mg /L Rifampacn, D16 - Daptomycin l6mg /L, V- 
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Figure 4.7: Median & inter -quartile range of MSSA -N recovery after 3 -hour 
exposure to a combination of 2 or 3 antibiotics at 128, 16 or 4mg /L concentrations. 
(G128 - 128mg /L Gentamicin, R4 - 4mg /L Rifampacn, D16 - Daptomycin 16mg /L, 
V- Vancomycin, CL- Clindamycin, CP- Ciprofloxacin, LIN -Linezolid) 
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4.2.4. Effect of combining antibiotics on their MBEC 
The results in Figures 4.4 - 4.7 were unexpected and potentially clinically 
relevant, as any antagonism may raise the MBEC above levels that are 
clinically attainable and predispose to treatment failure. Another series of 
experiments was therefore designed to investigate what effect the addition of 
a second antibiotic had on the MBEC of gentamicin. 
The experiments utilized the SOP and tested CNS -J and MSSA -N in 
biological triplicate. Six of the antibiotics were tested at fixed concentrations 
felt to represent likely in -vivo levels (section 4.1.2), combined with a range of 
gentamicin concentrations that varied from 8 -2048 mg /L. 
Both figures 4.8 and 4.9 demonstrate the same trends in both organisms. The 
addition of daptomycin, vancomycin and ciprofloxacin to gentamicin 
resulted in a similar or lower MBEC than when gentamicin was used as a 
single agent. Conversely, when rifampacin, clindamycin or linezolid was 
added to gentamicin then a much higher MBEC was recorded compared to 
when gentamicin is used as a single agent. Although it would have been 
interesting to investigate whether there were linear effects when altering the 
second antibiotic concentration, there were insufficient resources to perform 
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Figure 4.8a: Median log density (fitted circles) & inter -quartile ranges (bars) 
of MSSA -N recovery after 3 -hour exposure to gentamicin alone or in 
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Figure 4.8b: Median log density (fitted circles) & inter -quartile ranges (bars) 
of CNS -J recovery after 3 -hour exposure to gentamicin alone or in 
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Figure 4.9a: Median log density (fitted circles) & inter -quartile ranges (bars) 
of MSSA -N recovery after 3 -hour exposure to gentamicin alone or in 
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Figure 4.9b: Median log density (fitted circles) & inter -quartile ranges (bars) 
of CNS -J recovery after 3 -hour exposure to gentamicin alone or in 
combination with rifampacin, clindamycin or linezolid. 
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4.2.5. The fractional inhibitory concentration index 
In order to document the effect size of the apparent interactions seen, 
enabling comparisons with previous and future work, the data from Figures 
4.8 and 4.9 was analysed together with data from Figures 4.2 and 4.3. 
The Fractional Inhibitory Concentration (FIC) index291 is a method to detect 
synergism or antagonism between two antibiotics. It was adapted by this 
author to become the Fractional Biofilm Eradication Concentration (FBEC) 
index. 
FBEC = MBEC of antibiotic in combination / MBEC of antibiotic on its own 
FBEC index = FBEC (x) + FBEC (g) 
Where (x) is an antibiotic tested in combination with gentamicin (g). 
An FBEC index of 0.5 indicates a synergistic effect 
> 0.5 and <_ 1.0 an additive effect 
> 1.0 and <_ 4.0 an indifferent effect 
> 4.0 an antagonistic effect. 
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Antibiotic x Vanc Dapt Clinda Cipro Rifampacin Linezolid 
MBEC antibiotic 
x in combination 
MBEC antibiotic 













































FBEC Index Synergistic Additive Antagonistic Synergistic Antagonistic Antagonistic 
Table 4.2: Fractional biofilm eradication concentration index (FBEC) for MSSA -N. 
Efficacy of combinations in relation to antibiotics tested alone (data from Figures 
4.2, 4.8a and 4.9a). 
Antibiotic x Vanc Dapt Clinda Cipro Rifampacin Linezolid 
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in combination 













































FBEC Index Indifferent Additive Antagonistic Indifferent Antagonistic Antagonistic 
Table 4.3: Fractional biofilm eradication concentration index (FBEC) for CNS -J. 
Efficacy of combinations in relation to antibiotics tested alone (data from Figures 
4.2, 4.8b and 4.9b). 
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4.2.6. Establishing minimum inhibitory and minimum bactericidal 
concentrations 
The MIC is the lowest concentration of an antibiotic that will inhibit visible 
overnight growth of a bacterial culture. The MBC is the lowest antibiotic 
concentration that inhibits growth when the MIC sample is subsequently sub- 
cultured onto an antibiotic free substrate. The range is established by doubling 
up or down from lmg \ L. 
The micro -dilution method of the British Society of Antibiotic Chemotherapy 
(BSAC)156 was used to determine MIC and MBC for both the MSSA -N (reference 
ATCC 25923) and CNS -J strains of Staphylococcus spp. for 7 antibiotics: 
gentamicin; vancomycin; daptomycin with 50mg /L CaZ +; clindamycin; 
ciprofloxacin; rifampacin and linezolid. (The supplementation of 50 mg / L of 
Ca' has been shown to increase in -vitro activity of daptomycin when tested in 
broth and is recommended292). 
5ml LB overnight broths were cultured from cryo -preservative, plated onto LB 
agar and incubated overnight. Four morphologically similar colonies from 
either the MSSA -N or CNS -J strains were sampled from the LB agar plate with a 
sterile loop and sub -cultured in a 5m1 bottle of LB overnight. Growth controls 
were micro -diluted and plated on LB agar using the Miles -Misra method'. 
Samples were prepared in quadruplicate by adding 75.11 of inoculum to 7511 of 
LB containing antibiotic, in a range either side of the expected MIC 156, into each 
of the flat -bottomed 96 wells to establish a final suspension of 10 5 CFU / ml. The 
plates were taped shut, incubated statically in air at 37° for 20 hours and MIC 
identified as lowest value without visible growth. 
124 
To establish the MBC, 2001 samples from each aforementioned well and 
transferred into a new 96 well micro -titre plate containing 1800 of fresh LB and 
universal neutraliser (L- histidine, L- cysteine and reduced glutathione)249. These 
samples were also incubated statically in air at 37° for a further 24 hours before 
the MBC was recorded as the lowest value without visible growth. 
LB was chosen to facilitate comparison between the MIC and the MBEC found 
in the alginate bioassay. The MIC's were the same or within one double dilution 
of the suggested levels for the BSAC, except for rifampacin, which was, 5 fold 
different. The most likely reason for this would be the use of LB instead of 
Muller Hinton broth (MHB) that is more commonly used by the BSAC although 
other media are permitted for use in the test if they produce values that are 
within one dilution of the reference levell'6. The other anomaly was that 
clindamycin, which is normally regarded as bacteriostatic, had a MBC / MIC 
ratio of 2 (i.e. bactericidal) in both organisms. This was perhaps due to a post 
antibiotic effect in the sub -culture. 
As can be seen from the wide range of MIC / MBEC ratios (that were broader 
than the range of MBEC's alone) in Table 4.4, there was poor correlation 
observed between the MIC and MBEC. Rifampacin had the lowest MIC but 
equal highest MBEC and daptomycin had a relatively high MIC but the lowest 
MBEC. Therefore the common practice of selecting the antibiotics based solely 
on the MIC antibiogram seems misguided and may explain a proportion of the 
failures that are seen in clinical practice. 
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Mg / L Gent Vanc Dapto Clinda Cipro Rif Linez 
MIC 0.125 2 0.25 0.125 0.125 0.062 1 
MBC 0.5 2 0.5 0.25 0.25 0.5 8 
CNS-J MBC / MIC 4 1 2 2 2 8 8 
MBEC 32 >2048 32 >2048 >2048 >2048 >2048 
MBEC / MIC 256 >1024 128 >16,384 >16,384 >33,032 >2048 
MIC 0.25 1 0.25 0.125 0.5 0.125 2 
MBC 0.5 2 0.5 0.25 0.5 1 16 
MSSA- 
N MBC/MIC 2 2 2 2 1 8 8 
MBEC 256 >2048 16 >2048 >2048 >2048 >2048 
MBEC / MIC 1024 >2048 64 >16,384 >4096 >16,384 >1024 
Table 4.4: Ratios of MIC, MBC and MBEC (mg /L) of CNS -J and MSSA -N 
when exposed to the antibiotics: gentamicin; vancomycin; daptomycin with 
50mg /L Caz +; clindamycin; ciprofloxacin; rifampacin and linezolid. 
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4.3. Discussion 
The principle findings of this chapter were that 
i. There appears to be a poor correlation between the MIC of an 
antibiotic and the MBEC. 
ii. When used as single agents at clinically achievable doses, 
gentamicin and daptomycin were the only effective antibiotics. 
iii. Combining antibiotics, that were not effective as single agents, did 
not confer additional benefit. 
iv. Combining bactericidal antibiotics with gentamicin had some 
additive effects whilst combining it with antibiotics considered 
bacteriostatic, had a strongly antagonistic effect. 
4.3.1. Correlating MIC breakpoints and MBECs 
It is generally accepted that bacteria aggregated around a prosthesis in a 
biofilm are much more tolerant to antibiotics than when they are in a 
planktonic state66,1o9,293,294 The reasons for this have not been elucidated fully 
but they are most likely related to the higher proportion of the bacterial 
population that enter a dormant persister state, thereby protecting 
themselves from the effects of antibiotics and other stresses'. 
Antunes et al.296 tested 82 staphylococcal sp. isolated from patients and 
found no correlation between the MIC and MBEC for vancomycin with their 
ratio ranging between 1 and >64. Similar ranges in the MIC /MBEC ratio for 
multiple antibiotics have previously been published's'29'. This calls into 
question whether current clinical susceptibility testing is able to identify the 
most appropriate chemotherapeutics when treating prosthetic related 
infection. This view is supported by recent mathematical and continuous 
biofilm culture model comparing these pharmacokinetic/MIC indices, used 
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to establish breakpoints, with biological response against a MSSA29s. They 
found that the antibiotics, predicted to be effective by the traditional 
methods, never fully eradicated the biofilms which repopulated from the 
persisters whenever the antibiotic level receded between dosing periods. 
Our finding that gentamicin and daptomycin were the only effective single 
antibiotics examined in our study, is supported by some previous studies. 
Ceri et al. who tested the same MSSA -N strain ATCC 29213 using the Calgary 
biofilm device 109 found the MBEC of gentamicin to be within a clinically 
achievable dose whilst ciprofloxacin, clindamycin and vancomycin were 
more than a 1000x their MIC. Girard et 31.297 tested 21 clinical isolates of 
MSSA with seven antibiotics and found gentamicin to be the only effective 
antibiotic, however they also did not test daptomicin and their methods were 
not detailed enough to draw direct comparison with our results. Raad et a1.299 
used a modified Robbins device to culture 10 strains of MRSA in a biofilm 
state and found daptomycin to eradicate them effectively whilst vancomycin, 
linezolid and rifampacin were ineffective. Daptomicin has also been shown 
to be active against the stationary growth phase of MRSA which has been 
used as a proxy for organisms in biofilm30o 
4.3.2. Antibiotic characteristics 
The differences seen between the seven different antibiotics cannot easily be 
explained by their ability to penetrate the polysaccharide intercellular 
adhesin (PIA). Indeed gentamicin, ciprofloxacin301, daptomycin", 
rifampacin", linezolid30`l, and clindamycin30' have all demonstrated good 
penetration into staphylococcal biofilm whilst only vancomycin has been 
shown to be significantly hampered by it 301,30¢ 
This led to an enquiry as to whether gentamicin and daptomycin have a 
common mode of action that could explain their efficacy against 
staphylococcal biofilms. Daptomycin is a negatively charged cyclic 
lipopeptide that rapidly penetrates biofilm 302 and has a distinct mechanism 
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of action. Cat+ acts as a cross -bridge to enable it to insert into the cytoplasmic 
membrane, permitting escape of K+, Mgt+ and ATP 306,307, thereby 
depolarizing the membrane potential and leading to cell death . Gentamicin 
is a positively charged aminoglycoside that, unlike all other classes of 
ribosome inhibitors, causes the 30S ribosome to produce mistranslated 
proteins. These abnormal proteins are inserted into the cell membrane that 
sets up a positive feedback loop of increasing permeability, hyper - 
stimulation of the electron transfer chain and hydroxyl radical damage to the 
cell308. Although they have different modes of action they both deal a 
catastrophic blow to the integrity of the cell membrane. 
The finding that rifampacin combined with either vancomycin or 
ciprofloxacin didn't confer additional benefit was a surprise as it is 
commonly used in clinical situations with apparent success53. When Olson et 
al. 309performed an in -vitro study using CNS and a continuous flow chamber 
with steady state antibiotics the results were similar to ours, in that the 
addition of 12mg /L rifampacin to 40mg /L vancomycin did not result in 
additional killing However when they performed the experiment using a 
guinea pig cage tissue model they found it did significantly improve 
eradication of the 5- day -old CNS biofilm compared to monotherapy. 
Zimmerli et al. has published a similar model with a 24 hour old MSSA 
biofilm240 and found the combination of rifampacin (trough 1mg /L to peak 
8mg / L) and ciprofloxacin (trough 0.11mg / L to peak 1mg / L) or vancomycin 
(trough 3mg / L to peak 9mg / L) much more effective than monotherapy. 
A possible explanation for this discrepency may be in the dosing regimes, 
which are constant in -vitro but vary in -vivo, between peak bactericidal and 
trough sub inhibitory concentrations. Lewis295 previously postulated that 
cyclic dosing that allowed persisters to start repopulating the biofilm just as 
they are exposed to another bactericidal wave may eventually eradicate all 
persisters. The effect of the host's innate immune system might also be 
another obvious explanation for these discrepancies between laboratory and 
clinical studies. 
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4.3.3. Synergism and antagonism 
Finding that combining bactericidal antibiotics with gentamicin had an 
additive or synergistic effect against staphylococcal biofilm has been 
reported once before by Tsuji et al.310 using an endocardial vegetation model. 
They also found gentamin and daptomycin to be the most efficacious single 
antibiotics whilst vancomycin was ineffective. Their study reported for 
daptomycin, the addition of a single high dose of gentamicin provided 
synergistic, rapid concentration -dependent killing. The Calgary biofilm 
device has been used to analyse a large number of two and three drug 
combinations279 up to 256mg / L however the results of the study seem 
inconsistent with the MSC, being commonly less than the observed MIC. It 
seems possible that they may have had similar problems as this author in 
optimising the complex protocol 224. 
The results that combining gentamicin with the bacteriostatic antibiotics 
(linezolid, rifampacin, clindamycin) had a strongly antagonistic effect with 
gentamicin have, to the authors knowledge not been published before. 
Several commercial bone cements have been designed for treating prosthetic 
infection, which contain gentamicin and clindamycin. The rationale behind 
this was to broaden the antibiotic cover and also to improve the bactericidal 
effect. Neut et al.311 investigated its properties using a modified Robbins 
device and found that gentamicin / clindamycin cement coupons resisted 
colonization by MSSA more effectively than gentmicin alone. However the 
distribution of that data was not presented further than 'a combined SD in all 
21 samples of around 50%'. It would also been more enlightening if a biofilm 
had been allowed to form before adding the antibiotics, as this study might 
have represented more of a test of biofilm attachment than treatment. 
There are three postulates for the observed antagonism found in this present 
study. It seems the organisms either became more tolerant to the gentamicin, 
there was a chemical interaction between the two antibiotics rendering them 
less active, or there was methodological error. Given the effect was observed 
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with narrow inter- quartile ranges in three antibiotics for whom interactions 
have not been published before, the former seems most likely. 
4.3.4. Mechanisms for antibiotic tolerance 
Staphylococci have, as discussed in the section 1.3, a diverse network of 
regulators that modify gene expression and enable them to tolerate a wide 
range of environmental stresses which include antibiotics and cationic 
antimicrobial peptides (CAP's). They are able to alter the proportion of the 
negatively charged PIA and positively charged teichoic acids in their 
extracellular polymeric matrix and cell membrane via the GraRS system'. 
This confers them the ability to change their surface charge when stressed, 
making them more significantly tolerant to the positively charged CAP's, 
gentamicin and vancomyin. Interestingly this envelope stress response has 
previously not found to be induced by gentamicin, vancomycin or 
daptomycin313 but if they were inducible by bacteriostatic antibiotics this 
would be a possible explanation for our results and worthy of further study. 
An important paper from Kohanski et al.114 postulates the common final 
pathway for all bactericidal drugs as being an overwhelming oxidative 
stress. Hydroxyl radical formation, induced by bactericidal antibiotics, are 
the end product of an oxidative damage cellular death pathway involving a 
transient depletion of NADH by the electron transfer chain, destabilization of 
iron -sulfur clusters, and stimulation of the Fenton reaction. They also 
demonstrated that bacteriostatic drugs do not cause oxidative stresses or 
initiate the DNA damage response SOS system, even though rifampacin was 
shown to damage it. This enables one to deduce that the antagonism seen in 
this study, was not due to the activation of the SOS pathway mitigating the 
effects of oxidative stress caused by gentamicin. Perhaps the bacteriostatic 
agent further slows the metabolic rate of the organism and this relative lack 
of NADH protects it against hydroxyl radical formation induced by 
bactericidal antibiotics. It is also conceivable that as the bacteria senses the 
bacteriostatic antibiotic; a hitherto unexplained mechanism induces an 
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Figure 4.10: Spectrum of bacterial responses that antibiotics can induce. 
Reproduced from Surette et a1.132. 
4.3.5. Limitations of our experiments 
As Luria broth LB was the most effective media for the biofilm assay, it was 
also used to facilitate comparison when calculating the MIC and MBC. 
Compared to the more commonly recommended Mueller -Hinton broth, LB 
contains less divalent cations (Ca2 +, Mg2 +) and so theoretically can interfere 
with the binding of cationic antibiotics. It also contains less carbohydrate 
and so could potentially cause nutritional stress with longer -term growth. 
That said however, the MIC values for the reference strain MSSA -N were 
within one dilution (except rifampacin) of the Clinical and Laboratory 
Standards Institute values and therefore acceptable'''. 
Another possible bias in our results relates to the relatively short time the 
bacteria were exposed to the antibiotics so might under estimate the effect of 
antibiotics that display time -dependent killing232. The very high antibiotic 
concentrations that are seen initially, tail off rapidly174 (Figure 4.1) and unless 
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dosing is consistent with in vivo pharmokinetics then this short exposure 
time is reasonable to ensure conservative estimations of in vivo effects. Both 
mathematical and in vitro experiment models298 suggest that a successful 
chemotherapeutic regime would have to be rapidly bactericidal in the period 
that the dose dependent antibiotic is present at effective levels. 
This leads into another unavoidable limitation of the study, which is a lack of 
host immune system. This is likely to be one of the main reasons why 
regimes that have been demonstrated to be most effective in animal models' 
and clinical trials56 have generally not been replicated in biofilm models3°9. 
No evidence exists as to the proportions attributable to chemotherapy, 
bacterial virulence and host response in a success outcome. To minimize 
financial and ethical costs, it is important to continue to improve the in -vitro 
models until they more closely parallel biological effects in the clinical 
situation. This will never fully be realized however, as bacterial eradication is 
only one end -point to a good clinical outcome. Local and systemic side 
effects may be worse than the cure, as in the case of severe streptococcal soft 
tissue infection where the addition of the bacteriostatic agent clindamycin 
has been shown to reduce mortality compared to the bactericidal agents, by 
down -regulating the organism's exotoxin production whilst penicillins 
initially have the opposite effect, due to rapid cell lysisz°8. 
Acknowledgement is given to the fact that, only two strains of staphylococci 
were tested and that insufficient resources were available perform a full 
checkerboard with varying doses of both drugs in combination. The 
rationale for selecting the most appropriate conditions was listed previously 
(sections 1.5- 1.7) based on correlation with the literature review and current 
clinical practice. 
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4.3.6. Future research 
Recent efforts to augment the cellular uptake of gentamicin, either by 
degrading the integrity of the cell membrane or increasing the proton motive 
force have been described. Cationic antibacterial peptides (CAP's) are 
normally produced as part of the host's response but can be isolated from 
non -pathogenic bacteria and indolicidin cecropin A, melittin A amide 
(CAMA) and nisin have all shown to be synergistic with gentamicin against 
MRSA at clinically achievable doses228. The CAP's form complexes with the 
lipids in the cell membrane then aggregate, incorporate additional peptides, 
and form a pore that allows more gentamicin to enter the cell31' 
Both aminoglycoside uptake316 and hydroxy radical formation by bactericidal 
agents308 are energy dependent via the Proton Motive Force (PMF). Realising 
this Allison et al.107 did a number of experiments to investigate whether 
stimulating dormant persisters with metabolites could potentiate the effects 
of gentamicin. They showed that the if certain metabolites (glucose, 
mannitol, fructose or pyruvate) are transported to the cytoplasm, some by 
their specific phospho -transferase system enzymes; they enter glycolysis, 
where their catabolism generates NADH, and this NADH is then oxidized by 
enzymes in the electron transfer chain, which contribute to PMF. The 
elevated PMF facilitates the uptake of aminoglycosides, which bind to the 
ribosome and cause cell death via mistranslation and oxidative stresses 
resulting from a positive feedback'''. These effects were apparently seen 
without allowing the organisms to revert to a growth state. They also 
demonstrated this was effective in a mouse catheter biofilm model. However 




5.1.1. Summary of main findings 
The aim of this thesis has been to investigate whether staphylococcal biofilm, 
found in PJI, is susceptible to specific antibiotic combinations when delivered 
at clinically relevant doses. In order to do that most effectively, a new 
method to culture and assay the biofilm had to be developed, and validated 
to recognised standards. 
The research hypothesis has been to shown to be correct as only a minority of 
the 29 antibiotic combinations tested effectively eradicated the biofilm. An 
additive/ synergistic effect was seen between gentamicin some of the other 
cidal antibiotics. However, the antagonism seen between gentamicin and the 
bacteriostatic drugs tested, has important potential implications for current 
clinical practice. 
5.1.2. Different perspectives 
Through the course of the thesis, a number of arguments have been 
advanced. The popularity of joint replacement has provided bacteria with an 
immuno -incompetent niche to exploit as a biofilm (section 1.3). Rather than 
representing a distinct phenotye, biofilms seem to share many of the 
metabolic characteristics of the persister and SCV's (section 1.4.5) and it is 
feasible all three may be part of the same continuum, driven by schohastic 
gene responses to the different micro -electrochemical conditions they are 
exposed to. 
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Clinical experience dictates that antibiotic therapy alone is insufficient to 
eradicate PJI and without thought of how to: optimise the host's immune 
response; debride all necrotic tissues; temporarily remove immuno- 
incompetent niches; select how and which antibiotics to deliver in order to 
effectively eradicate both the remaining biofilm and intra- cellular bacteria, 
then success is more likely to be achieved by good fortune than good clinical 
care. 
5.1.3. The road to rational decision making 
Evidence of the very poor correlation between the planktonic susceptibility 
tests, currently used to guide treatment, and the antibiotics that are actually 
effective against staphylococcal biofilm, is presented in section 4.2.6. There 
appears to be a disconnect between the current susceptibility methods using 
breakpoint determination and the high antibiotic concentrations local 
delivery can achieve. Also, the results presented in section 4.2.1, that most 
antibiotics even if delivered in very high concentrations, appear ineffective in 
this model, prompt further thought. Of the seven antibiotics tested, 
daptomycin was the only one, if administered systemically, (section 1.6.1) 
that would have been likely to achieve the levels necessary to be effective 
against these strains. Gentamicin was the only other effective mono -therapy 
in this model but at levels only achievable with local administration (section 
1.7) presumably due in part to its favorable PK -PD profile (section 1.5.2). 
One of the most interesting findings of this research is the observed 
antagonism between clinically achievable doses of gentamicin and the three 
bacteriostatic agents (linezolid, clindamicin and rifampacin) that would 
necessitate between 8 and 32 times more gentamicin being administered 
before it is effective against the same biofilm (Tables 4.2 & 4.3). Clindamicin 
is commonly used in conjunction with gentamicin in an ALAC and 
rifampacin is frequently administered as a systemic adjunct as recommended 
by the recent American guidelines in PJI2Ó. Gentamicin's entry into the cell is 
diminished when the bacteria becomes less metabolically active, the cell 
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membrane potential reduces as a consequence thereby conferring gentamicin 
tolerance. It seems plausible that the bacteriostatic antibiotics might be able 
to induce the antagonism seen in this study, by changing the membrane 
potential, either by blocking key metabolic pathways or perhaps more likely 
given the short time frame in which they seem to be acting, via the toxin - 
antitoxin system. 
Although the alginate model is seen to meet previously defined standards of 
an acceptable biofilm assay, it is still too labour intensive to be useful in 
clinical medicine without further modification. Repeatable antibiosis was 
most variable around the critical MBEC and was perhaps due to threshold 
response phenomena. Another difficulty in this area of research is defining 
when an organism is non -viable, as persisters may have a very long lag 
phase and require specific growth conditions before they are culturable in 
vitro. In terms of the future directions of this thesis, a non -invasive 
continuous flow biofilm model would be most useful to confirm our findings 
as well as further investigation of the induction of cell envelope responses 
and metabolite assisted eradication. 
If the same antagonistic trends are found, then an in -vivo model could be 
justified to test the hypothesis that the addition of bacteriostatic agents 
initially antagonises the bactericidal effects of gentamicin. Bacteriostatic 
antibiotics are likely, on the basis of published clinical series, to be beneficial 
in the long run especially as they readily penetrate and concentrate in human 
cytoplasm, where gentamicin and daptomycin have minimal penetration. 
Perhaps a regime where bacterostatic antibiotics are withheld until such time 
as the antibiotics, found to be rapidly effective against the extracellular 
biofilm, fall below their MBEC with time. 
Whilst would be hubris for man to contemplate exerting ultimate control 
over staphylococci, our growing understanding of how they are regulated is 
presenting new therapeutic targets which may allow us to modulate their 
growth allowing both our species to live together harmoniously. 
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